Curriculum Vitae and Bibliography Paul Haluska, Jr., MD, PhD
PERSONAL INFORMATION
Place of Birth: Elizabeth, NJ Citizenship: United States
Work Address: Merck Corporation 126 E. Lincoln Ave Rahway, New Jersey 07065 732-594-9106 email Address: [email protected]
Home Address: 80 Randall Road Princeton, New Jersey 08540
Additional Information: Married, Spouse - Vanessa Fell Haluska Children - Luke Andrew Haluska and Elise Marie Haluska
PRESENT ACADEMIC RANK AND POSITION
Consultant - Division of Medical Oncology, Department of Oncology, 06/24/2006 - 2015 Mayo Clinic, Rochester, Minnesota Deputy Director - Mayo Clinic Phase I Program 05/29/2009 - 2015 Assistant Professor of Pharmacology - College of Medicine, Mayo 12/01/2009 - 2015 Clinic Associate Professor of Oncology - College of Medicine, Mayo Clinic 6/2011- 2015 Co-Director – Mayo Clinic Phase I Program 1/2014 – 1/2015 Director – Mayo Clinic Phase I Program 1/2015 – 4/2015 Global Director of Scientific Affairs, Oncology- Global Center for 4/2015 – Present Scientific Affairs, Merck Research Labs
EDUCATION
College of Arts and Sciences, Indiana University, Bloomington 1988 - 1992 BS, Biochemistry Robert Wood Johnson Medical School, University of Medicine and 1993 - 2000 Dentistry of New Jersey MD/PhD, M.D., Ph.D. Program Graduate School of Biomedical Sciences/UMDNJ-Robert Wood 1995 - 1998 Johnson Medical School, Rutgers The State University of New Jersey PhD, Pharmacology Internal Medicine Program, Clinical Investigator Program, Mayo 2000 - 2003 Graduate School of Medicine Residency, Internal Medicine Medical Oncology Fellowship Program, Clinical Investigator Program, 2003 - 2006 Mayo Graduate School of Medicine Fellowship, Medical Oncology
BOARD CERTIFICATION(S)
American Board of Internal Medicine Internal Medicine 2003 Medical Oncology 2006
LICENSURE
Minnesota 43661
HONORS/AWARDS
Glaxo Wellcome Oncology Clinical Research Scholar Award - 1997 American Association for Cancer Research Workshop New Jersey Cancer Research Award for Scientific Excellence - Rhone- 1998 Poulenc Rorer Oncology Clinician Investigator - General Mills Foundation 2003 Loan Repayment Program - National Institutes of Health 2003 - 2005 Chief Resident - Mayo Graduate School of Medicine-Clinical 2003 - 2005 Investigator Program Merit Award - American Society of Clinical Oncology 2004 Methods in Clinical Cancer Research Participant - American Society of 2004 Clinical Oncology/American Association for Cancer Research Workshop Molecular Biology in Clinical Oncology Participant - American 2005 Association for Cancer Research/American Society of Clinical Oncology Workshop Paul Calabresi Program Career Development Award - K12 - National 2006 Cancer Institute Young Investigator Award - American Society of Clinical Oncology 2006 Loan Repayment Program - National Institutes of Health 2007 - 2010 Mayo Clinic Breast SPORE Career Development Award - Mayo Clinic 2007 - 2009 Mayo Clinic Ovarian SPORE Career Development Award - Mayo Clinic 2009 - 2011
PREVIOUS PROFESSIONAL POSITIONS AND MAJOR APPOINTMENTS
Assistant Professor of Oncology - College of Medicine, Mayo Clinic 04/01/2006 - 2011 Senior Associate Consultant - Division of Medical Oncology, 07/01/2006 - 06/23/2009 Department of Oncology, Mayo Clinic, Rochester, Minnesota
PROFESSIONAL & COMMUNITY MEMBERSHIPS, SOCIETIES AND SERVICES (*indicates office held)
Professional Memberships & Services
American Association for Cancer Research *Member 2004 - Present
Career Development Committee *Member 2004 - 2007
Publications Committee *Member 2004 - 2007
Clinician Investigator Committee *Member 2003 - 2005
Mayo Clinic Fellows Association *Member 2000 - 2006
Minnesota Medical Association *Member 2000 - 2015
Minnesota Ovarian Cancer Alliance *Advisory Group Member 2007 - 2015
Oncology Research Committee *Member 2003 - 2004
NCI Investigational Drug Steering Committee * Signal Transduction Task Force Member 2009 - 2013 * Full Member 2014- 2015
ECCO/ESMO/AACR/EORTC Flims Methods in Clinical Cancer Research, 2013- Present Faculty
Study Section, Department of Defense * Breast Cancer Research Program, Team Award Panel 2010 - 2013 * Breast Cancer Research Program, Transformative Visionary Award and 2011 Collaborative Innovator Award Panel
Study Section, Susan G. Komen For The Cure * Post-Doctoral Fellow Review Panel 2011 - 2012
Gynecologic Oncology Group (GOG) * Developmental Therapeutics Committee, Member 2012 - 2015
Study Section, National Institutes of Health * DMP (Drug Metabolism and Pharmacology), Ad hoc member 2013 - 2014 * MMTR (Mouse Models for Translational Research, Chair 2014 - Present
American Society of Clinical Oncology (ASCO) * Member 2003 - Present * Scientific Program Committee, Gynecological Cancers Track, Member 2012 - 2015 * Scientific Program Committee, Gynecological Cancers Track, Leader 2013 - 2014 * Cancer Education Committee, Member 2013 - 2015
EDUCATIONAL ACTIVITIES Mentorship Individual and Timeframe & Outcomes Current Status Position Description Sagar, Malvika 2006 - 2007 Co-Author on Resident, Pediatrics, Research Trainee manuscript Upland PA Hou, Xiaonan 2007 - Present Author on 3 Converted to staff position Postdoctoral Fellow presentations; 2 as Senior Research manuscripts, Technician additional manuscripts pending, 2 industry contract funded Kahraman, Fatih 2008 (Summer) Completed Medical School Research Trainee Training in Turkey Weroha, S. John 2008 - Present Published 2 Research phase of Clinician Investigator manuscripts; author Clinician Investigator on 3 presentations; 2 Program in Oncology successful grant application Costello, Brian 2008 - Present Successful Grant Staff- Division of Medical Oncology Fellow Application- work Oncology, Mayo Scholars related to grant Program ongoing McKian, Kevin 2009 - Present Published manuscript Clinical Fellow in Oncology Fellow Hematology/Oncology Duane, Sarah 2009 (Summer) Graduated college Summer (Carleton), currently Undergraduate applying to medical school Research Student Wahner-Hendrickson, 2009 - Present 3 manuscripts In clinical component of Andrea published Clinician Investigator Clinician Investigator Program in Hematology/Oncology Farzan, Thahir 2009 - 2010 Manuscript co-autors Completed fellowship; Gynecological under consideration. Practicing in Texas as Oncology Fellow Gynecological oncologist Glaser, Gretchen 2010 - 2011 Two manuscripts in Completed fellowship; Gynecological development, one just Practicing in Virginia as Oncology Fellow submitted to Gynecological oncologist Gynecologic Oncology Jacob, Kristina 2011 - 2012 Two first author Clinical component of Gynecological manuscripts pending Gynecological Oncology Oncology Fellow Fellowship Becker, Marc 2010 - Present 2 First Author Post-doctoral Fellow Post-Doctoral Fellow Publications and third pending, multiple additional co-authors, Pilot Grant Awards, T32 Awardee Enderica Gonzalez, 2011 - 2012 First author and 2 Finishing Medical School Sergio secondary co-author Visiting Medical manuscripts pending Student (Ecuador) Al Hilli, Mariam 2012-2013 First author Clinical component of Gynecological manuscript in Gynecological Oncology Oncology Fellow development, co- Fellowship author on 2 additional manuscripts, Industry contract funded. Madde, Ankitha 2013 Completed Project Attending college- High School Honors Characterizing BRCA University of Pittsburgh Student mutation in ovarian tumor McKinstry, Sarah 2012-2013 First author In Epidemiology graduate Research Trainee manuscript in program at Emory. development Kumar, Amanika 2013-Present Started July 2013 Gynecological Oncology Fellow Tienchaiananda, 2013-2015 Started May 2013 Piyawan, Research Fellow Bocanega, Brandon 2013 Started September High School Honors 2013 Student Zayed, Amira 2013 Research Fellow Lodhia, Kunal 2014 Research Fellow
INSTITUTIONAL/DEPARTMENTAL ADMINISTRATIVE RESPONSIBILITIES, COMMITTEE MEMBERSHIPS AND OTHER ACTIVITIES (* indicates office held)
Mayo Clinic 2004 - 2005 Mayo Clinic Cancer Center, Concept Review Committee, Member Shared Resource Advisory Committee 2007 - 2014 BAP User Oversight Committee 2007 - 2014 Mayo Clinic Cancer Center, Scientific Review Committee, Member 2011 - 2015 IACUC Committee, Member 2015
PRESENTATIONS
International The IGF-1R/IR inhibitor, BMS-554417 has in vitro and in vivo activity. 11/10/2005 - 11/12/2005 Haluska P, Carboni J, Loegering D, Lee F, Saulnier M, Frennesson D, Attar R, Kalli K, Conover C, Kaufmann S, Gottardis M, Erlichman C. Poster Presentation The Role of the IGF System in Cancer Taormina, Italy
Hormonal Adjuvancy 09/15/2006 - 09/16/2006 Invited Oral Presentation VI International Symposium State of the Art in the management of Breast Cancer Lima, Peru
Hormonal Therapy in Metastatic Breast Cancer 09/15/2006 - 09/16/2006 Invited Oral Presentation VI International Symposium State of the Art in the management of Breast Cancer Lima, Peru
HER receptor signaling confers resistance to the insulin-like growth factor 09/16/2008 - 09/20/2008 1 receptor inhibitor, BMS-536924. Paul Haluska, Joan M. Carboni, Cynthia TenEyck, Ricardo M. Attar, Xiaonan Hou, Chunrong Yu, Malvika Sagar, Tai W. Wong, Marco M. Gottardis, and Charles Erlichman. Poster Presentation Fourth International Congress of the GRS and the IGF Society Genova, Italy
Bi-directional resistance pathways relevant to anti-IGF-1R targeted 09/16/2008 - 09/20/2008 therapy: Pathway to Clinical Development. Oral Presentation Fourth International Congress of the GRS and the IGF Society Genova, Italy
The insulin-like growth factor pathway-the key to overcoming resistance 10/03/2008 - 10/05/2008 to cancer therapy? Oral Presentation 2nd World Conference of Magic Bullets Nurnberg, Germany
Novel Targeted Therapy 01/15/2009 - 01/20/2009 Invited Oral Presentation The 3rd Middle East Best of CTRC-AACR San Antonio Breast Cancer Symposium Riyadh, Saudi Arabia
Molecular Profiling for Guiding Therapeutics 01/15/2009 - 01/20/2009 Invited Oral Presentation The 3rd Middle East Best of CTRC-AACR San Antonio Breast Cancer Symposium Riyadh, Saudi Arabia
Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal 03/22/2009 - 03/24/2009 antibody CP-751,871 in patients with refractory adrenocortical carcinoma Haluska P, Worden F, Olmos D, Yin D, Schteingart, Batzel G, Paccagnella ML, de Bono J, Gualberto A, Hammer G. Poster Presentation Targeted Anticancer Therapies (TAT) Amsterdam, Netherlands
Phase II Trial of Lapatinib in Combination with Weekly Topotecan in 03/22/2009 - 03/24/2009 Patients with Platinum-Refractory/Resistant Ovarian and Primary Peritoneal Carcinoma Oberg A, Dakhil S, Allen Ziegler K, Rowland K, Hartmann L, Moore D, Keeney G, Peethambaram P, Haluska P. Poster Presentation Targeted Anticancer Therapies (TAT) Amsterdam, Netherlands
Biomarkers in Anti-IGF-1R Targeted Therapy 04/2009 Invited Oral Presentation Oncology Advisory Board Meeting, Hoffman-La Roche Munich, Germany
Current IGF-1R Targeted Clinical Studies in Breast Cancer 04/2009 Invited Oral Presentation Oncology Advisory Board Meeting, Hoffman-La Roche Munich, Germany
Insulin Like Growth Factor Signaling and Cancer 10/12/2009 Invited Oral Presentation Nanjing University- School of Medicine Nanjing, China
Molecular Targeted Therapy in Ovarian Cancer (Terapia blanco molecular 08/25/2010 - 08/28/2010 en Cancer de Ovario) Invited Oral Presentation Seventh Congress of Medical Oncology: Towards Personalized Oncology (VII Congresso Peruano de Oncologia Medica: Hacia La Oncologia Personalizada) Cusco, Peru
Platinum-Resistant Ovarian Cancer: New Alternatives (Cancer de Ovario 08/25/2010 - 08/28/2010 Platino resistente: Nuevas alternativas) Invited Oral Presentation Seventh Congress of Medical Oncology: Towards Personalized Oncology (VII Congresso Peruano de Oncologia Medica: Hacia La Oncologia Personalizada) Cusco, Peru
Chemotherapy for Patients with Ovarian Cancer 11/18/2010 - 11/21/2010 III Curso Internacional de Oncologia Y Enfermeria Oncologica Guayaquil, Ecuador
Chemotherapy for Patients with Cervical Cancer 11/18/2010 - 11/21/2010 III Curso Internacional de Oncologia Y Enfermeria Oncologica Guayaquil, Ecuador
Phase I Trial of Figitumumab and Pegvisomant in Patients with Advanced 03/07/2011 - 03/09/2011 Solid Tumors Haluska P, Dudek AZ, Bono P, Sleight B, Joensuu H, Juergens H, and Pollak M. Poster Presentation Targeted Anticancer Therapies (TAT) Paris, France
Breast Cancer – Entering the Molecular Age 02/10/2012 - 02/11/2012 Invited Oral Presentation 2012 Ramathibodhi-Mayo Joint Conference Bangkok, Thailand
Advancing the treatment of HER-2 positive breast cancer 02/10/2012 - 02/11/2012 Invited Oral Presentation 2012 Ramathibodhi-Mayo Joint Conference Bangkok, Thailand
Ovarian Avatar Project: A model system for individualizing ovarian cancer 03/08/2012 - 03/10/2012 therapy. Haluska P, Oberg AL, Glaser G, Gonzalez SE, Becker MA, Jacob KA, Pennil CC, Fink SR, Kalli KR, Swisher EM, Jenkins RB, Sarkaria JN, Karlan BY, Weroha SJ Poster Presentation 10th International Congress on Targeted Anticancer Therapies (TAT) Amsterdam, The Netherlands
Gynecologic cancer case presentations 10/4/2012 - 10/5/2012 Roundtable discussions Problems of Oncology: Opinions from Two Continents Kaliningrad, Russian Federation
Adjuvant therapy for resected ovarian cancer 10/4/2012 - 10/5/2012 Management of metastatic ovarian cancer Management of cervix cancer Invited Oral Presentation Problems of Oncology: Opinions from Two Continents Kaliningrad, Russian Federation
Phase I study of figitumumab and pegvisomant in patients with advanced 10/17/2012 - 10/20/2012 solid tumors Paul Haluska, Uta Dirksen, Arkadiusz Z. Dudek, Petri Bono, Heikki Joensuu, Heribert Juergens, Barbara Sleight, and Michael Pollak Oral Presentation The 6th International Congress of the GRS and IGF Society Munich, Germany
A Phase 1 Study of MEDI-573, an Investigational Monoclonal Antibody 11/6/2012 - 11/9/2012 That Targets IGF-I and IGF-II: Safety, Pharmacokinetics, and Antitumor Activity in Adults With Advanced Solid Tumors Paul Haluska, Michael Menefee, Elizabeth Plimack, Jonathan Rosenberg, Donald Northfelt, Theresa LaVallee, Li Shi, Xiang-Qing Yu, Jaye Viner, Patricia LoRusso Poster Presentation 24th EORTC-NCI-AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics Dublin, Ireland
Ovarian Avatar Models Predictive of Platinum Response In Ovarian 3/4/2013 - 3/6/2013 Cancer Patients Weroha SJ, Becker MA, Harrington SC, Goodman K, Gonzalez SE, Al Hilli M, Butler KA, Kalli KR, Oberg AL and Haluska P. Oral Presentation 11th International Congress on Targeted Anticancer Therapies Paris, France Role of Pharmacokinetics and Pharmacodynamics in Clinical Trials 06/20/2014 – 06/28/2014 Methods in Clinical Cancer Research Films, Switzerland
National Sequential camptothecin and etoposide in the treatment of refractory 05/31/1996 malignancies Toppmeyer D, Haluska P, Li X-G, Goodin S, Orlick M, Aisner J, Rubin EH Annual Retreat on Cancer Research New Jersey
Identification of Human Topoisomerase I-binding Proteins Using the Two- 05/31/1996 Hybrid System in S. cerevisiae Haluska P and Rubin EH Annual Retreat on Cancer Research New Jersey
Analysis of topoisomerase I and II protein levels in a clinical trial of 10/21/1996 - 10/24/1996 sequential camptothecin and etoposide Saleem A, Toppmeyer D, Gupta E, Zamek R, Much J, Ibrahim N, Bindi M, Haluska P, Li X-G, Goodin S, Aisner J, Natelson E, Giovanella B and Rubin EH Poster Presentation The Seventh Conference on DNA Topoisomerases in Therapy- NYU Medical Center and The Kaplan Cancer Center
Helicase Binding by the Amino Terminus of Human Topoisomerase I 04/12/1997 - 04/16/1997 Haluska P and Rubin EH Oral Presentation 1997 AACR Annual Meeting San Diego, California
Identification of Novel Topoisomerase Binding Proteins 05/30/1997 Invited Plenary Speaker for presentation of abstract Annual Retreat on Cancer Research New Jersey
A Phase I Pharmacokinetic and Pharmacodynamic Study of 05/30/1997 Camptothecin and Etoposide in Patients with Advanced Malignancies Toppmeyer D, Gupta E, Saleem A, Zameck R, Much J, Ibrahim N, Bindi H, Haluska P, Li XG, Goodin S, Aisner J, Natelson N, Giovanella B, Rubin EH Annual Retreat on Cancer Research New Jersey
A Novel RS Protein Binds Human Topoisomerase I 03/28/1998 - 04/01/1998 Haluska P, Saleem A, Rubin EH Poster Presentation 1998 AACR Annual Meeting
Characterization of a Novel Topoisomerase I-Binding Protein 05/29/1998 Haluska P, Saleem A, Rubin EH Annual Retreat on Cancer Research New Jersey
Identification of a novel protein that binds to human topoisomerase I 04/10/1999 - 04/14/1999 Rasheed Z, Haluska P, Saleem A, Rubin EH Poster Presentation 1999 AACR Annual Meeting
Interesting Case Presentations- Oral Presentation 07/24/2003 - 07/26/2003 Haluska P Big Sky Oncology Update 2003 Big Sky, Montana
A phase I trial of gemcitabine, 17-allylaminogeldanamycin (17-AAG) and 06/05/2004 - 06/08/2004 cisplatin in solid tumor patients Haluska P, Toft D. O., Steinmetz S. M., Furth A., Mandrekar S., Stensgard B. A., McCollum A. K., Hanson L. J., Adjei A. A., Erlichman C Poster Presentation 2004 ASCO Annual Meeting New Orleans, Louisiana
SAR of a series of 3-[6-(4-substituted-piperazin-1-yl)-4-methyl-1H- 03/13/2005 - 03/17/2005 benzimidazol-2-yl]-1H-pyridin-2-one inhibitors of the IGF-1 receptor kinase with in vivo antitumor activity Saulnier MG, Velaparthil U, Frennesson1 DB, Liu P, Zimmermann K, Sang X, Eummer J, Bedingfield K, Lee FT, Carboni JM, Vyas DM, Haluska P, Loegering DA, Kaufmann SH, Erlichman C, Attar R, Gottardis G, and Wittman M. Proceedings of the 229th National Meeting of the American Chemical Society San Diego, California
BMS-554417, an Inhibitor of the Insulin-Like Growth Factor I Receptor 04/16/2005 - 04/20/2005 and Insulin Receptor, Inhibits Proliferation and Induces Mitochondrial Pathway-Mediated Apoptosis in Cancer Cell Lines Haluska P, Carboni JM, Loegering DA, Lee FY, Saulnier M, Frennesson D, Attar R, Kalli KR, Conover CA, Mandrekar SJ, Kaufmann SH, Gottardis M and Erlichman C Poster Presentation 2005 AACR Annual Meeting Anaheim, California
BMS-554417, an Inhibitor of the Insulin-Like Growth Factor I Receptor 07/17/2005 - 07/22/2005 and Insulin Receptor, Inhibits Proliferation and Induces Mitochondrial Pathway-Mediated Apoptosis in Cancer Cell Lines Haluska P, Carboni JM, Loegering DA, Lee FY, Saulnier M, Frennesson D, Attar R, Kalli KR, Conover CA, Mandrekar SJ, Kaufmann SH, Gottardis M and Erlichman C Poster Presentation Gordon Conference-Molecular Therapeutics of Cancer New London, New Hampshire
Clinical Case Studies in Supportive Care Options 06/02/2006 - 06/06/2006 Historical overview of the treatment of lung and colorectal cancers and supportive care options. Invited Oral Presentation 2006 ASCO Annual Meeting Atlanta, Georgia
The Refractory Ovarian Cancer Patients: What are the Causes of 08/01/2006 - 08/05/2006 Resistance to Chemotherapy Invited Oral Presentation 16th Annual Mayo Clinic Hematology/Oncology Reviews; 8th Annual Fellows' Research Presentations and 1st Cancer Research Review Amelia Island, Florida
Co-inhibition of the IGF-1R and HER family of receptors stimulates 04/14/2007 - 04/18/2007 synergistic cell death in human ovarian cancer cells. Paul Haluska, Chunrong Yu, Joan M. Carboni, Diane C. Soeffker, Tai W. Wong, Mark G. Saulnier, Ricardo M. Attar, Mark Wittman, Scott H. Kaufmann, Marco Gottardis, Charles Erlichman Poster Presentation 2007 AACR Annual Meeting Los Angeles, California
Apoptotic and anti-proliferative effects of the dual insulin-like growth 04/14/2007 - 04/18/2007 factor-1 (IGF-1R)/insulin receptor inhibitor, BMS 536924, in acute myelogenous leukemia. Andrea E. Wahner Hendrickson, Judith E. Karp, Joan Carboni, Ricardo M. Attar, B. Douglas Smith, Mark Whittman, Marco Gottardis, Paul J. Haluska, Scott H. Kaufmann. Poster Presentation 2007 AACR Annual Meeting Los Angeles, California
Phase I dose escalation study of the anti-IGR monoclonal antibody CP- 06/01/2007 - 06/05/2007 751,871 in patients with refractory solid tumors P. Haluska, H. M. Shaw, G. N. Batzel, L. R. Molife, A. A. Adjei, T. A. Yap, M. L. Roberts, D. Yin, A. Gualberto, J. S. de Bono Poster Presentation 2007 ASCO Annual Meeting Chicago, Illinois
Circulating tumor cells expressing the insulin growth factor-1 receptor 06/01/2007 - 06/05/2007 (IGF-1R); Method of detection, incidence and potential applications. J. S. de Bono, A. Adjei, G. Attard, M. Pollak, P. Fong, P. Haluska, L. Roberts, D. Chainese, L. Terstappen, A. Gualberto Oral Presentation 2007 ASCO Annual Meeting Chicago, Illinois
Insulin-like growth factor binding protein-5 is overexpressed in breast 07/07/2007 - 07/10/2007 cancer cells resistant to IG-1R inhibition Paul Haluska, Cynthia Ten Eyck, Joan M Carboni, Yan W Asmann, Mark G. Saulnier, David Frennesson, Ricardo M Attar, Cheryl A Conover, Mark D Wittman, Marco Gottardis and Charles Erlichman Poster Presentation 15th SPORE Investigators' Workshop Baltimore, Maryland
Co-inhibition of the IGF-1R and HER family of receptors stimulates 07/22/2007 - 07/27/2007 synergistic cell death in human ovarian cancer cells. Haluska P, Yu C, Carboni J, Soeffker D, Wong T, Saulnier M, Attar R, Wittman M, Kaufmann S, Gottardis M, Erlichman C Poster Presentation Molecular Therapeutics of Cancer Gordon Research Conference New London, New Hampshire
Safety, tolerability and preliminary efficacy of the anti-IGF-IR monoclonal 10/22/2007 - 10/26/2007 antibody CP-751,871 in patients with sarcomas and adrenocortical tumors. Olmos D, Molife R, Okuno S, Worden F, Hammer G, Yap T, Shaw H, Schuetze S, Roberts L, Gualberto A, de-Bono J, Haluska P Poster Presentation AACR-NCI-EORTC International Conference San Francisco, California
Breast Cancer Landscape 12/03/2007 Invited Oral Presentation Bristol Myers Squibb Advisory Board Meeting: IGF-1R Inhibitor Program New York, New York
Phase II study of carboplatin and pemetrexed for the treatment of 03/09/2008 - 03/12/2008 platinum-sensitive recurrent ovarian cancer. Discussant for Paper Matulonis U.A., Penson R.T., Campos, S.M., Lee, H., Lee J., Kendall D.L., Krasner C.N., Berlin S., Roche M. , Duska L.R., and Horowitz, N.S 39th Annual Meeting, Society of Gynecological Oncology Tampa, Florida
Phase I study of 17-allylamino-17 demethoxygeldanamycin (17-AAG), 03/20/2008 - 03/22/2008 gemcitabine (Gem) and/or cisplatin (CDDP) in solid tumor patients. P. Haluska, B.A. Stensgard, R. Qin, S.J. Felten, G.N. Batzel, S.P. Ivy, D.O. Toft, C. Erlichman. Poster Presentation 6th International Symposium on Targeted Anticancer Therapies Bethesda, Maryland
Characterization of NSCLC patients responding to anti-IGF-IR therapy. 05/30/2008 - 06/03/2008 Gualberto A, Melvin CL, Dean A, Ang AL, Reynolds JM, Lee AV, Terstappen LW, Haluska P, Lipton A, Karp DD. Oral Presentation 2008 ASCO Annual Meeting Chicago, Illinois
HER receptor signaling confers resistance to IGF-1R targeted therapy 05/30/2008 - 06/03/2008 Paul Haluska, Joan M. Carboni, Cynthia TenEyck, Ricardo M. Attar, Xiaonan Hou, Chunrong Yu, Malvika Sagar, Tai W. Wong, Marco M. Gottardis and Charles Erlichman Poster Presentation 2008 ASCO Annual Meeting Chicago, Illinois
Safety, pharmacokinetics and preliminary activity of the anti-IGF-IR 05/30/2008 - 06/03/2008 antibody CP-751,871 in patients with sarcoma. Olmos D, Okuno S, Schuetze SM, Paccagnella ML, Yin D, Gualberto A, Worden FP, Haluska P, De Bono JS, Scurr M Oral Presentation 2008 ASCO Annual Meeting Chicago, Illinois
High activity of the anti-IGF-IR antibody CP-751,871 in combination with 05/30/2008 - 06/03/2008 paclitaxel and carboplatin in squamous NSCLC. Karp DD, Paz-Ares LD, Novello S, Haluska P, Garland L, Cardenal F, Blakely LJ, Eisenberg PD, Gualberto A, Langer CJ Oral Presentation 2008 ASCO Annual Meeting Chicago, Illinois
Population pharmacokinetics of CP-751,871, a monoclonal antibody 05/30/2008 - 06/03/2008 against IGF-1 receptor, in patients with multiple myeloma or solid tumors. Yin D, Paccagnella ML, Lacy MQ, De Bono JS, Haluska P, Gualberto A, Sharma A Poster Discussion Presentation 2008 ASCO Annual Meeting Chicago, Illinois
Phase I trial of Intraperitoneal (IP) administration of a measles virus (MV) 05/30/2008 - 06/03/2008 derivative expressing the human carcinoembryonic antigen (CEA) in recurrent ovarian cancer (OvCa). Galanis E, Hartmann LC, Cliby W, Peethambaram PP, Long HJ, Kaur JS, Haluska P, Sloan JA, Peng K, Russell SJ Poster Presentation 2008 ASCO Annual Meeting Chicago, Illinois
Gynecological Malignancies 08/04/2008 - 08/08/2008 Session Chair 18th Annual Hematology/Oncology Reviews Amelia Island, Florida
New and Emerging Treatments in Ovarian Cancer: A 2008 Update. 08/04/2008 - 08/08/2008 Invited Oral Presentation 18th Annual Hematology/Oncology Reviews Amelia Island, Florida
Management of HER2+ metastatic breast cancer: Current standard and 08/04/2008 - 08/08/2008 novel approaches. Invited Oral Presentation 18th Annual Hematology/Oncology Reviews Amelia Island, Florida
BMS-536924 02/2009 Invited Oral Presentation 10th Annual Targeted Therapies of the Treatment of Lung Cancer Santa Monica, CA
Targeting IGF signaling in breast cancer to overcome resistance to 03/22/2009 - 03/27/2009 hormonal therapy. Haluska P, Hou X, Carboni J, Macedo L, Harrington S, Attar R, Ingle J, Suman V, Brodie A, Gottardis M. Poster Presentation Gordon Research Conference Ventura, California
Insulin Receptor A isoform and erbB receptor up-regulated in response to 03/22/2009 - 03/27/2009 IGF-1R targeted therapy. Harrington S, Hou X, Macedo L, Weroha J, Brodie A, Haluska P. Poster Presentation Gordon Research Conference Ventura, California
Hormonal therapies differentially enhance insulin receptor isoform A and 04/18/2009 - 04/22/2009 erbB receptor up-regulation in response to IGF-1R inhibitor MK-0646 in vivo. Hou X, Harrington S, Macedo L, Weroha J, Brodie A, Haluska P. Poster Presentation 100th Annual AACR Meeting 2009 Denver, Colorado
Combined estrogen signaling inhibition and IGF-1R/InsR inhibition with 04/18/2009 - 04/22/2009 BMS-754807 in estrogen dependent breast cancer model has synergistic antitumor activity in vitro and in vivo. Hou X, Carboni J, Macedo L, Harrington S, Finckenstein F, Brodie A, Gottardis M. Haluska P, Poster Presentation 100th Annual AACR Meeting 2009 Denver, Colorado
Continued high activity of figitumumab (CP-751,871) combination therapy 05/29/2009 - 06/02/2009 in squamous lung cancer. D. D. Karp, S. Novello, F. Cardenal, P. Haluska, L. J. Blakely, L. Garland, L. G. Paz-Ares, M. P. Dolled-Filhart, E. D. Johnson, A. Gualberto Poster Presentation 2009 ASCO Annual Meeting Orlando, Florida
Applying IGF Signaling to Current Breast Cancer Therapy 06/04/2009 Invited Oral Presentation Medimmune Meeting Gaithersburg, Maryland
IGF-Signaling Blockade Overcomes Resistance to Hormonal Therapy in 07/16/2009 Metastatic Breast Cancer Models Oral Presentation TBCRC Meeting Dallas, Texas
Gynecological Malignancies 07/30/2009 - 08/01/2009 Session Chair 19th Annual Mayo Hematology/Oncology Reviews Amelia Island, Florida
New Therapies in GYN Management 07/30/2009 - 08/01/2009 Invited Oral Presentation 19th Annual Mayo Hematology/Oncology Reviews Amelia Island, Florida
Advances in Gyn Malignancies 08/2009 19th Annual Mayo Hematology/Oncology Reviews Amelia Island, Florida
Complete IGF Signaling Blockade by the Dual-Kinase Inhibitor, BMS- 12/9/2009 - 12/13/2009 754807, Is Sufficient To Overcome Tamoxifen and Letrozole Resistance In Vitro and In Vivo. Haluska P, Hou X, Huang F, Harrington SC, Greer A, Macedo LF, Brodie A, Evans DB, Carboni JM, Gottardis MM Poster Discussion San Antonio Breast Cancer Symposium San Antonio, TX
Low expression of insulin-like growth factor binding proteins predicts poor 02/06/2010 outcomes in ovarian cancer patients. Haluska P, Harrington SC, Farzan T, Winterhoff BJ, Goodman KM, Kalli KK, Gottfried KE AACR/JCA Joint Conference: Genomics, Epigenomics, and the Development of Novel Therapeutics Waikoloa, Hawaii
Review: San Antonio Breast Cancer Symposium 1/25/2010 Web-based seminar- Amgen Haluska P.
BMS-754807 02/24/2010 - 02/24/2010 Invited Oral Presentation 10th Annual Targeted Therapies of the Treatment of Lung Cancer Santa Monica, CA
Phase I trial of the combined targeting of the Hedgehog (GDC-0449) and 04/19/2010 EGFR pathways (erlotinib) in pancreatic cancer. AACR 101st Annual Meeting 2010 Washington, District of Columbia
Regulation of hormone resistant breast cancer by IGF and insulin system 05/20/2010 signaling Haluska P (oral plenary presentation) 2010 Breast SPORE Roundtable Meeting National Harbor, Maryland
N0733: Phase II trial of capecitabine and lapatinib plus or minus 06/06/2010 cixutumumab in HER2-positive breast cancer Haluska P, Reinhiolz MM, Dueck AC, Linden HM, Lingle WL, Bernath AM, Arbushites MC, Youssoufian H, Chen HX, Perez EA (Abstract #TPS129) Onconet Steering Committee Meeting 2010 ASCO Annual Meeting Chicago, Illinois
Phase I trial of dasatinib (D) and lapatinib (L). 06/07/2010 J Clin Oncol 28:15s, 2010 (suppl; abstr 2610). Co-authors on poster: Erlichman C, Menefee ME, Northfelt DW, Qin R, Reid JM, Oursler M, Marks R, Molina JR, Koch K 2010 ASCO Annual Meeting Chicago, Illinois
Development Therapeutics – Clinical Pharmacology and Immunotherapy. 6/7/2010 Erlichman C, Menefee M, Northfelt D, Qin R, Oursler MJ, Marks R, Haluska P, Molina J, Koch KM. Poster Presentation 2010 ASCO Annual Meeting Chicago, Illinois
N0733: Phase II trial of capecitabine and lapatinib +/- cixutumumab in 6/7/2010 HER2 positive breast cancer. Haluska P, Reinholz MM, Dueck AC, Linden HM, Lingle WL, Bernath AM, Arbushites MC, Youssoufian H, Chen HX, Perez A. Trials in Progress Poster Presentation 2010 ASCO Annual Meeting Chicago, Illinois
IGF-1 Inhibition in the treatment of Breast Cancer 08/06/2010 CME presentation, St. Vincent Hospital Green Bay, WI
Chemotherapy (Standard and New) 11/12/2010 Invited Oral Presentation Mayo Clinic Arizona Mayo Clinic Multidisciplinary Update in Breast Diseases Scottsdale, AZ
Approved Targeted Therapies 11/12/2010 Invited Oral Presentation Mayo Clinic Arizona Mayo Clinic Multidisciplinary Update in Breast Diseases Scottsdale, AZ
Endocrine Therapies 11/13/2010 Invited Oral Presentation Mayo Clinic Arizona Mayo Clinic Multidisciplinary Update in Breast Diseases Scottsdale, AZ
BMS-754807 02/23/2011 Invited Oral Presentation 11th Annual Targeted Therapies of the Treatment of Lung Cancer Santa Monica, CA
Insulin Receptor Isoform A is the Predominant Isoform in Breast 02/27/2011 - 3/4/2011 Cancer Patients Poster Presentation Gordon Conference: Insulin-Like Growth Factors in Physiology & Disease Ventura, CA
The Role of InsR Isoforms and IGFBPs in Sensitivity to IGF-1R Targeting 03/14/2011 Invited Oral Presentation Spring 2011 NCI CTEP Early Drug Development Meeting Bethesda, MD
Phase II trial of the dual IGF-1R/IR inhibitor BMS-754807 with or without 06/06/2011 letrozole in aromatase inhibitor-resistant breast cancer. Haluska P, Dhar A, Hou X, Huang F, Nuyten DSA, Park JS, Brodie AH, Ingle JN, Carboni JM, Gottardis MM, Wolff AC, Finckenstein FG. Trials in Progress Poster Presentation 2011 ASCO Annual Meeting Chicago, Illinois
IGF Targeting in Cancer: Trials and Tribulations 06/06/2011 Invited Oral Presentation 2011 Endocrine Society Annual Meeting Boston, Massachusetts
Regulation of Hormone-resistant Breast Cancer by IGF and Insulin 07/28/2011 System Signaling. Haluska P, Hou X, Dhar A, Yee D, Suman VJ, Harrington SC, Finckenstein F, Ingle JN. Poster Discussion NCI Translational Science Meeting 2011 Washington, DC
Current Status of PARP inhibitors in Ovarian Cancer 07/28/2011 Invited Oral Presentation NCI Translational Science Meeting 2011 Washington, DC
IGF Signaling as a Mechanism of Resistance to Hormonal Therapy in 08/30/2011 Breast Cancer Invited Oral Presentation Women’s Cancer/Cell Signaling Lecture Series University of Minnesota Minneapolis, Minnesota
Mayo Ovarian Living Tumor Bank as a Drug Development Tool 09/08/2011 Invited Oral Presentation WCRC Seminar Series University of Pittsburgh Cancer Institute Pittsburgh, PA
MEDI-573--a novel approach to IGF-1R and IR-A signaling inhibition by 09/09/2011 blocking IGF ligands: Phase 1 PK/PD, safety data, and disease linkage studies in breast cancer P. Haluska, J. Huang, B. Lam, X. Chen, W. Huang, P. LoRusso, M.E. Menefee, T. LaVallee, Y. Yao, J. Viner Poster Presentation ASCO Breast Cancer Symposium San Francisco, CA
MEDI-573—a novel approach to IGF-1R and IR-A signaling inhibition by 09/09/2011 blocking IGF ligands: Phase 1 PK/PD, safety data, and disease linkage studies in breast cancer Oral Presentation P. Haluska, J. Huang, B. Lam, X. Chen, W. Huang, P. LoRusso, M.E. Menefee, T. LaVallee, Y. Yao, J. Viner ASCO Breast Cancer Symposium San Francisco, CA
IGF Signaling as a Target in Cancer- Trials and Tribulations 11/2/2011 Invited Oral Presentation Cancer Center Grand Rounds: http://videos.med.wisc.edu/videos/36384 University of Wisconsin Paul P. Carbone Comprehensive Cancer Center Madison, WI
IGFBP ratio confers resistance to IGF targeting and correlates with 12/6/2011 - 12/11/11 increased invasion and poor outcome in breast tumors Poster Presentation Becker MA, Hou X, Harrington SC, Carboni JM, Gottardis MM, Haluska P. San Antonio Breast Cancer Symposium San Antonio, Texas
BMS-754807 02/22/2012 - 02/25/2012 Invited Oral Presentation 11th Annual Targeted Therapies of the Treatment of Lung Cancer Santa Monica, CA
Ovarian Avatar Project 2/1/2013 Invited Oral Presentation Visiting Professor Mayo Clinic - Jacksonville, Florida
Systemic Therapies for Gynecological Malignancies 2/15/2013 - 2/16/2013 Invited Oral Presentation Individualized Breast, Gynecologic, and Colon Cancer Management: New Data and Updates Relevant to Patient Care Jacksonville, Florida
Anti-IGF ligand Antibodies 2/21/2013 - 2/23/2013 Invited Oral Presentation 11th Annual Targeted Therapies of the Treatment of Lung Cancer Santa Monica, CA
In vivo antitumor activity of the PARP inhibitor niraparib (MK-4827) in 09/18/2013 - 09/21/2013 homologous recombination deficient and proficient ovarian cancer AACR Advances in Ovarian Cancer Research Miami, Florida Selected Oral Presentation by Mentee, Dr. Mariam AlHilli
Anti-IGF Ligand Antibody: BI836845 and MEDI-573 02/19/2014 – 02/20/2014 14th Annual Targeted Therapies of the Treatment of Lung Cancer Invited Oral Presentation Session Chair Santa Monica, CA
Of Mice and (Wo)men: The Ovarian Avatar Project 05/20/2014 Memorial Sloan Kettering Cancer Center Grand Rounds Oral Presentation New York, NY
The Ovarian Avatar Project: Of Mice and (Wo)men 05/21/2014 Mayo Clinic Arizona Grand Rounds Oral Presentation Scottsdale, AZ
The Mayo Ovarian Program: Of Mice and (Wo)men 5/29/2014 University of Illinois Grand Rounds Oral Presentation Chicago, IL
Novel Targeting Approaches in Ovarian Cancer 05/20/2014 – 06/03/2014 Oral abstract session Discussant
Ovatars: Using Patient-Derived Xenografts for Selecting Best Therapies Educational session Invited Speaker
Randomized Phase II Trial of Capecitabine and Lapatinib +/- IMC-A12 in Patients with HER2+ Breast Cancer Previously Treated with Trastuzumab and an anthracycline and/or a taxane, NCCTG N0733 (Alliance) Poster Presentation P. Haluska, A.M. Bernath Jr., K.V. Ballman, A.C. Dueck, H.M. Linden, M.P. Goetz, D.W. Northfelt, X. Hou, K.S. Tenner, P. Tienchaiananda, L.M. Flickinger, B. Chen, H.X. Chen, W.L. Lingle, C.M. Pellegrino, R.W. Sponzo, M.M. Reinholz, E.A. Perez,
2014 Annual ASCO Meeting Chicago, IL
Palliative chemotherapy approaches to recurrent disease and novel 07/14/2014 biologic therapies. ABS GYN School Invited Speaker Chicago, IL
Gynecologic Oncology 08/08/2014 24th Annual Mayo Clinic Hematology/Oncology Review CME Course Invited Speaker Amelia Island, FL
Novel strategies to target the C5 subclass of high-grade serous ovarian 11/09/2014 cancer using patient-derived xenografts. Poster Presentation 15th Biennial Meeting of the International Gynecologic Cancer Society Melbourne, Australia Homologous recombination deficiency (HRD) score and niraparib efficacy 11/18/2014 – 11/21/2014 in high grade ovarian cancer Oral Presentation P Haluska, K Timms, M Al Hilli, Y Wang, A-R Hartmann, J Jones, A Gutin, Z Sangale, C Neff, J Lanchbury, L Rudolph-Owen, MA Becker, X Hou, S Agarwal and K Wilcoxen
26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Barcelona, Spain 18-21 November 2014.
Regional Non-surgical Free Intraperitoneal Air 10/25/2002 Allen RD, Haluska P, Bergstrom L Minnesota American College of Physician Annual Meeting Bloomington, Minnesota
Postinfectious Glomerulonephritis & Furosemide-Induced Interstitial 10/25/2002 Nephritis Allen RD, Haluska P, Bergstrom L Minnesota American College of Physician Annual Meeting Bloomington, Minnesota
Ovarian Cancer - Can We Do Better? 09/29/2006 Grand Rounds - St. Joseph's Hospital St. Paul, Minnesota
Targeted Therapy 06/11/2007 - 06/13/2007 Oral Presentation 5th Annual NCCTG Patient Advocate Symposium Rochester, Minnesota
Ovarian Cancer: Can We Do Better? 10/03/2007 Grand Rounds - Lake Region Health Care Hospital Fergus Falls, Minnesota
Molecular Targeted Treatment 06/09/2008 - 06/11/2008 Oral Presentation 6th Annual NCCTG Patient Advocate Symposium Rochester, Minnesota
Special Treatment for Triple Negative Disease and HER2 Positive Breast 11/19/2009 - 11/21/2009 Cancer. Invited Oral Presentation Mayo Multidisciplinary Update in Breast Diseases Rochester, Minnesota
Breast Cancer-Entering the Molecular Age 9/15/2011 Invited Oral Presentation 2011 Current Issues in Cancer Care Conference: Innovative Approaches To Cancer Rochester, Minnesota
Making Sense of Clinical Trials in Ovarian Cancer- “Why me, Why now?” 10/20/2011 Oral Presentation Minnesota Ovarian Cancer Alliance Sponsored Lecture Bloomington, Minnesota
Chemoradiotherapy for Locally Advanced Cervical Cancer 1/7/2014 Oral Presentation Mayo Clinic Gynecology Oncology Conference Rochester, MN
The AVATAR Project 3/11/2014 Oral Presentation 3/18/2014 Heme/Onc/BMT Professional Development Series Mayo Continuing Nursing Education Rochester, MN
Overexpression of IGF-2 in primary patient ovarian cancer tumorgrafts 4/7/2014 increases bowel and thoracic metastasis. Poster Presentation AACR Annual Meeting San Diego, CA
Utilizing ER Target genes as biomarkers of endocrine response in serous 4/7/2014 ovarian carcinoma. Poster Presentation AACR Annual Meeting San Diego, CA
Of Mice and (Wo)men: The Ovarian Avatar Project 05/20/2014 Oral Presentation Grand Rounds, Memorial Sloan Kettering Cancer Center. New York, NY
Novel targeting approaches in ovarian cancer. 05/31/2014 Invited Discussant ASCO Annual Meeting Chicago, IL
Ovatars: Using patient-derived xenografts for selecting best therapies. 05/31/2014 Invited Oral Presentation ASCO Annual Meeting Chicago, IL
Randomized phase II trial of capecitabine and lapatinib +/- IMC-A12 in 06/02/2014 patients with HER2+ breast cancer previously treated with trastuzumab and an anthracycline and/or a taxane, NCCTG N0733 (Alliance) Poster Presentation ASCO Annual Meeting Chicago, IL
Role of pharmacokinetics and pharmacodynamics in clinical trials 06/24/2014 Methods in Clinical Cancer Research Films, Switzerland
Chemoradiotherapy for locally advanced cervical cancer. 07/07/2014 Gynecology Oncology Conference Mayo Clinic Rochester, MN
Palliative chemotherapy approaches to recurrent disease and novel 07/14/2014 biologic therapies Invited Oral Presentation GYN School Chicago, IL
Gynecologic Oncology 08/08/2014 Invited Oral Presentation 24th Annual Mayo Clinic Hematology/Oncology Review CME Course Amelia Island, FL
Lessons learned from targeting the IGF-1R and implications for cancer 10/01/2014 prevention Invited Oral Presentation Thirteenth Annual AACR International Conference on Frontiers in Cancer Prevention Research New Orleans, LA
The Mayo Ovarian Avatar Program: Of Mice and (Wo)men 10/06/2014 Keynote Speaker University of Alabama at Birmingham Comprehensive Cancer Center 17th Annual Research Retreat Birmingham, Alabama
CLINICAL PRACTICE, INTERESTS, AND ACCOMPLISHMENTS Ovarian cancer, Breast Cancer, Phase I clinical trials, Patient-derived xenografts
RESEARCH INTERESTS Drug Development, Preclinical Research, Patient-Derived Xenografts, Ovarian Cancer, Breast Cancer
RESEARCH GRANTS AWARDED
Active Grants Federal Principle R01 CA184502 (Haluska) 05/13/14 – 05/12/18 Investigator National Cancer Institute (PQD5) Avatar-directed Treatment for Ovarian Cancer
Principle UM1 CA186686-1 (Haluska) 4/7/14-3/31/19 Investigator National Cancer Institute NCI Experimental Therapeutics- Clinical Trials Network with Phase 1 Emphasis
Project P50 CA116201 (Ingle - PI) 09/01/10 - 09/01/16 Co-Leader National Cancer Institute Mayo Clinic Breast Cancer SPORE “Project #3- Regulation of Hormone Resistant Breast Cancer by IGF and Insulin System Signaling’
Project P50 CA136393 (Kaufmann - PI) 1/1/11 - 11/10/15 Co-Leader; National Cancer Institute Core Leader Mayo Clinic Ovarian Cancer SPORE Title - “Project #4-Mechanism-guided development of an innovative therapy for ovarian cancer
Principle Phase I/II Trial of the combination of the PARP 10/2011- Current Investigator inhibitor ABT-888 with floxuridine in epithelial ovarian, primary peritoneal and fallopian tube cancers
Principle MC1012, Phase I study of the combination of the 3/2011 - Current Investigator VEGFR inhibitor, AZD2171, and MEK inhibitor, AZD6244, in the treatment of solid malignancies
Principle N0733 “Randomized Phase II Trial of Capecitabine 8/2009 - Current Investigator and Lapatinib with or without IMC-A12 in Patients with HER2 Positive Breast Cancer Previously Treated with Trastuzumab and an Anthracycline and/or a Taxane Foundation Co-Principle MNP #13.28 (Haluska and Kaufman) 03/01/14 – 2/28/16 Investigator Minnesota Partnership for Biotechnology and Medical Genomics Genomic Approach for Targeted Immunotherapy Against Ovarian Cancer
Project Leader Ovarian Cancer Research Foundation - 1/1/2013 - 1/1/2016 OCRF258797 Title- “The FA-BRCA pathway and response to platinum and PARP inhibitors in ovarian, tubal and peritoneal carcinomas.” Elizabeth Swisher- Overall PI
Industry Program TRIO 014 in: TRIO 014, A randomized, double-blind, 01/01/2010 - 12/31/2015 Director / placebo controlled, multi-center, phase II study of Principal adding AMG 479 to first line chemotherapy in patients Investigator with optimally debulked (<1 cm) Epithelial ovarian cancer. Funded by Cancer International Research Group. (TRIO 014) Program MCR CD-ON-MEDI-573-1030: A Phase 1b/2 01/01/2012 - 12/31/2014 Director / Randomized Study of MEDI-573 in Combination with Principal an Aromatase Inhibitor (AI) Versus AI Alone in Investigator Women with Metastatic Breast Cancer (MBC). Funded by MedImmune, Inc. (Protocol Number CD- ON-MEDI-573-1030) Program Optimization of niraparib in the treatment of ovarian 10/01/2013 - 09/30/2015 Director / cancer. Funded by Tesaro. Principal Investigator Program CO-338-017: A Phase 2, Open-Label Study of 12/01/2013 - 11/30/2015 Director / Rucaparib in Patients with Platinum-Sensitive, Principal Relapsed, High-Grade Epithelial Ovarian, Fallopian Investigator Tube, or Primary Peritoneal Cancer. Funded by Clovis. (Protocol CO-388-017) Program Evaluation of strategies to circumvent 12/06/2013 - 12/05/2015 Director / chemoresistance in ovarian Pdx trial. Funded by Principal Genentech Incorporated. Investigator Program BBI608-201, A Phase Ib/II Clinical Study of BBI608 04/01/2014 - 03/31/2016 Director / Administered with Paclitaxel in Adult Patients with Principal Advanced Malignancies. Funded by Boston Investigator Biomedical, Inc. (Protocol BB1608-201)
Completed Grants Federal Co- R01 CA104378-04 Karnitz (PI) 12/01/06 - 02/28/09 Investigator Therapeutic targeting of HSP90-dependent signaling
Awardee P50 CA 116201-03 Ingle (PI) 09/2007 - 09/2009 Breast SPORE Career Development Award. Title: “Therapeutic Strategy for Targeting the Insulin-Like Growth Factor Receptor in Breast Cancer”.
Co- Breast SPORE Developmental Research Project. 09/2005 - 08/2006 Investigator Funded by National Institutes of Health. (P50 CA116201)
Awardee / K12 CA090628-05 Hartmann (PI) 7/1/2006 - 6/30/2010 Scholar Paul Calabresi/Mayo Clinical Oncology Research Training Program Title - “Targeting Minimal Residual Disease in Ovarian Cancer with Growth Factor Receptor Inhibition”.
Awardee P50 CA136393 (Hartmann - PI) 12/1/09 - 12/1/11 National Cancer Institute Ovarian SPORE Career Development Award. Title: “Development and Application of Clinically Relevant In Vivo Models of Ovarian Cancer”.
Co-Principle P50 CA136393 (Hartmann - PI) 10/1/2011 - 9/30/2012 Investigator National Cancer Institute (with Dr. Ovarian SPORE Developmental Award. Title: Becker and “Applying In Vivo Tumorgraft Models to Target Bowel Weroha) Metastasis in Ovarian Cancer”.
Co-Principle P50 CA136393 (Hartmann - PI) 10/1/2011 - 9/30/2012 Investigator National Cancer Institute (with Dr. Ovarian SPORE Developmental Award. Title: Shridhar) “Mechanistic basis for drug synergy between metformin and inhibitors of IGF-R1/InsR in ovarian cancer”.
Co- U01 CA069912-17 (Erlichman - PI) 03/01/11 - 02/28/13 Investigator National Cancer Institute Phase I Clinical Trials of Anticancer Agents
Consultant Z1041 in: Z1041, A Randomized Phase III Trial 10/2007 - 09/2012 Comparing a Neoadjuvant Regimen of FEC-75 Followed By Paclitaxel Plus Trastuzumab With a Neoadjuvant Regimen of Paclitaxel Plus Trastuzumab Followed by FEC-75 Plus Trastuzumab in Pts W/ Palpable & Operable Breast Cancer.
Foundation Principle Minnesota Ovarian Cancer Alliance 10/01/10 - 10/01/11 Investigator Title- “Generation of Clinically Relevant Ovarian Cancer Xenograft Models.”
Project Project 1: Haluska: Growth factor inhibition: IGF and 12/2007 - 12/2010 Director HER systems in: Improving Therapeutic Outcomes for Ovarian Cancer. Funded by Andersen Foundation. (ANDERSEN #13 P-5)
Principal Therapeutic implications of crosstalk between the IGF 07/2006 - 06/2007 Investigator and HER system in ovarian cancer. Funded by Phi Beta Psi Sorority.
Project Project 1-“Inhibition of the IGF Network in Ovarian 01/01/06 - 01/01/09 Director Cancer”. Program Project Grant, Novel Therapeutics in Ovarian Cancer Andersen Foundation (Hartmann and Kaufmann Overall co-PIs)
Consultant P50-CA-58183, Neoadjuvant trial of lapatinib for the 10/2008 - 09/2010 treatment of women with DCIS breast cancer in: Neoadjuvant trial of lapatinib for the treatment of women with DCIS breast cancer. Funded by Breast Cancer Research Foundation. (P50 BCRF)
Principal Targeting Crosstalk between the Insulin-like growth 07/2006 - 06/2007 Investigator factor I receptor and the HER family receptors in Breast Cancer. Funded by American Society of Clinical Oncology.
Mayo Clinic Principal CA 116201-03 Breast SPORE Career Development 09/2007 - 08/2008 Investigator Award (Mayo Cancer Center Funds). Funded by Other Mayo. (P50 CA 116201) Principal Genetic Markers as Predictors of Toxicity in Patients 05/2009 - 04/2010 Investigator Receiving Intraperitoneal Chemotherapy for Ovarian Carcinoma. Funded by Mayo Clinic.
Industry
Principal Merck Onconet MCR MK-0646-027 Phase I Parallel 01/2011 - 01/2013 Investigator Protocol of MK-0646 + MK-2206 and MK-0646 + MK- 0752 Doublets
Principal N0733 - Capecitabine + Lapatinib +/- IMC-A12 04/2008 - 03/2012 Investigator Collection Only Budget. Funded by GlaxoSmithKline. (N0733/111739)
Principal N0733 - Capecitabine + Lapatinib +/- IMC-A12 04/2008 - 03/2012 Investigator Collection Only Budget. Funded by ImClone Systems Incorporated. (N0733)
Principal Amendment #1(Replacement)IMCL CP13-0604 A 04/2008 - 04/2012 Investigator Phase 2 Randomized, Multicenter Study of IMC-A12 as a Single Agent or in Combination With Antiestrogens in Postmenopausal Women With Hormone Receptor-Positive Advanced or Metastatic Breast Cancer in: Amendment #1 (Replacement) IMCL CP13-0604 A Phase 2 Randomized, Multicenter Study of IMC-A12 as a Single Agent or in Combination With Antiestrogens in Postmenopausal Women With Hormone Receptor-Positive Advanced Metastatic Breast Cancer After Progression. Funded by ImClone Systems Incorporated. (IMCL CP13- 0604)
Program N0733 - Capecitabine + Lapatinib +/- IMC-A12 04/01/2008 - 03/31/2010 Director / Collection Only Budget. Funded by ImClone Systems Principal Incorporated. (NCCTG N0733) Investigator Program Amendment #1(Replacement)IMCL CP13-0604 A 04/04/2008 - 04/03/2010 Director / Phase 2 Randomized, Multicenter Study of IMC-A12 Principal as a Single Agent or in Combination With Investigator Antiestrogens in Postmenopausal Women With Hormone Receptor-Positive Advanced or Metastatic Breast Cancer in: Amendment #1 (Replacement) IMCL CP13-0604 A Phase 2 Randomized, Multicenter Study of IMC-A12 as a Single Agent or in Combination With Antiestrogensin Postmenopausal Women With Hormone Receptor-Positive Advanced Metastatic Breast Cancer After Progression. Funded by ImClone Systems Inclorporated. (IMCL CP13- 0604) Program Changes in Estrogen-Responsive Breast Cancer In 06/01/2009 - 05/31/2010 Director / Response to Treatment with MK-0646 (IGF1R mAb) Principal and MK-8669 (mTOR inhibitor). Funded by Merck & Investigator Co., Inc. Program MK646 correlative studies (Merck) in: Changes in 06/01/2009 - 05/31/2010 Director / Estrogen-Responsive Breast Cancer In Response to Principal Treatment with MK-0646 (IGF1R mAb) and MK-8669 Investigator (mTOR inhibitor). Funded by Merck & Co., Inc. Program MK646 correlative studies (Merck) Aim #1 in: 06/01/2009 - 05/31/2010 Director / Changes in Estrogen-Responsive Breast Cancer In Principal Response to Treatment with MK-0646 (IGF1R mAb) Investigator and MK-8669 (mTOR inhibitor). Funded by Merck & Co., Inc. Program MK646 correlative studies (Merck) Aims #3/5 in: 06/01/2009 - 05/31/2010 Director / Changes in Estrogen-Responsive Breast Cancer In Principal Response to Treatment with MK-0646 (IGF1R mAb) Investigator and MK-8669 (mTOR inhibitor). Funded by Merck & Co., Inc. Program TRIO 015 in: TRIO 015 -Multicenter Open Label 08/01/2009 - 07/31/2011 Director / Phase II Study of Efficacy & Safety of AMG 479, a Principal Fully Human Monoclonal Antibody Against Insulin- Investigator Like Growth Factor Type I Receptor...Ovarian Cancer. Funded by Cancer International Research Group. (MCCRC / TRIO 015) Program A4021040 “Phase I Safety and Tolerability Study of 08/03/2009 - 08/02/2011 Director / Figitumumab Combined with Pegvisomant in Patients Principal with Advanced Solid Tumors”. Funded by Pfizer Inc. Investigator (Protocol A4021040)
PATENTS
Title Patent number Date filed Date issued Diagnostic and therapeutic use of TOPORS US 2003176343 01/09/2003 09/18/2003 Inventors: Rubin, Eric H.; Saleem, Ahamed; Rasheed, Zeshaan; Haluska, Paul, Jr
BIBLIOGRAPHY Peer-reviewed Articles
1. Li X-G, Haluska P, Hsiang YH, Bharti AK, Kufe DW, Liu LF, Rubin EH. Involvement of amino acids 361 to 364 of human topoisomerase I in camptothecin resistance and enzyme catalysis. Biochem Pharmacol 1997 Apr 4; 53(7):1019-27. PMID:9174116.
2. Haluska P, Saleem A, Edwards TK, Rubin EH. Interaction between the N-terminus of human topoisomerase I and SV40 large T antigen. Nucleic Acids Res 1998 Apr 1; 26(7):1841-7. PMID:9512561. PMCID:PMC147454.
3. Ahmed F, Vyas V, Saleem A, Li X-G, Zamek R, Cornfield A, Haluska P, Ibrahim N, Rubin EH, Gupta E. High-performance liquid chromatographic quantitation of total and lactone 20(S)camptothecin in patients receiving oral 20(S)camptothecin. J Chromatogr B Biomed Sci Appl 1998 Apr 10; 707(1-2):227-33. PMID:9613954.
4. Gupta E, Toppmeyer D, Zamek R, Much J, Ibrahim N, Goodin S, Kane M, Aisner J, Li X-G, Haluska P, Medina M, Cornfield A, Vyas V, Natelson E, Giovanella B, Saleem A, Rubin EH. Clinical evaluation of sequential topoisomerase targeting in the treatment of advanced malignancy. Cancer Therapeutics 1998 Nov-Dec; 1(5):292-301.
5. Haluska P, Saleem A, Rasheed Z, Ahmed F, Su EW, Liu L, Rubin EH. Interaction between human topoisomerase I and a novel RING finger/arginine-serine protein. Nucleic Acids Res 1999 Jun 15; 27(12):2538-44. PMID:10352183. PMCID:PMC148458.
6. Haluska P, Adjei AA. Receptor tyrosine kinase inhibitors. Curr Opin Investig Drugs 2001; 2(2):280-286. PMID:11816845.
7. Dy GK, Haluska P, Adjei AA. Novel pharmacological agents in clinical development for solid tumours. Expert Opin Investig Drugs 2001 Dec; 10(12):2059-88. PMID:11772306.
8. Haluska P, Dy GK, Adjei AA. Farnesyl transferase inhibitors as anticancer agents. Eur J Cancer 2002 Sep; 38(13):1685-700. PMID:12175684.
9. Haluska P, Luetmer PH, Inwards CY, Afessa B, Shives TC, Ingle JN. Complications of therapy and a diagnostic dilemma case of Case 3. Diagnostic dilemma: Sarcoidosis simulating metastatic malignancy. J Clin Oncol 2003 Dec 15; 21(24):4653-4. PMID:14673057.
10. Haluska P, Carboni JM, Loegering DA, Lee FY, Wittman M, Saulnier MG, Frennesson DB, Kalli KR, Conover CA, Attar RM, Kaufmann SH, Gottardis M, Erlichman C. In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417. Cancer Res 2006 Jan 1; 66(1):362-71. PMID:16397250.
11. de Bono JS, Attard G, Adjei A, Pollak MN, Fong PC, Haluska P, Roberts L, Melvin C, Repollet M, Chianese D, Connely M, Terstappen LW, Gualberto A. Potential applications for circulating tumor cells expressing the insulin-like growth factor-I receptor. Clin Cancer Res 2007 Jun 15; 13(12):3611-6. PMID:17575225.
12. Haluska P, Shaw HM, Batzel GN, Yin D, Molina JR, Molife LR, Yap TA, Roberts ML, Sharma A, Gualberto A, Adjei AA, de Bono JS. Phase 1 dose escalation study of the anti-IGF-IR monoclonal antibody CP-751,871 in patients with refractory solid tumors. Clin Cancer Res 2007 Oct 1; 13(19):5834-40. PMID:17908976.
13. Sekulic A, Haluska P Jr, Miller AJ, Genebriera De Lamo J, Ejadi S, Pulido JS, Salomao DR, Thorland EC, Vile RG, Swanson DL, Pockaj BA, Laman SD, Pittelkow MR, Markovic SN. Melanoma Study. Malignant melanoma in the 21st century: the emerging molecular landscape. Mayo Clin Proc 2008 Jul; 83(7):825-46. PMID:18613999. PMCID:2739389. NIHMS:124777.
14. Haluska P, Carboni JM, TenEyck C, Attar RM, Hou X, Yu C, Sagar M, Wong TW, Gottardis MM, Erlichman C. HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924. Mol Cancer Ther 2008 Sep; 7(9):2589-98. Epub 2008 Sep 02. PMID:18765823. PMCID:PMC2614316. NIHMS:68744. DOI:10.1158/1535-7163.MCT-08- 0493.
15. *Weroha SJ, Haluska P. IGF-1 receptor inhibitors in clinical trials--early lessons. J Mammary Gland Biol Neoplasia 2008 Dec; 13(4):471-83. Epub 2008 Nov 21. PMID:19023648. PMCID:PMC2728362. NIHMS:124775. DOI:10.1007/s10911-008-9104-6.
16. Santisteban M, Reiman JM, Asiedu MK, Behrens MD, Nassar A, Kalli KR, Haluska P, Ingle JN, Hartmann LC, Manjili MH, Radisky DC, Ferrone S, Knutson KL. Immune-induced epithelial to mesenchymal transition in vivo generates breast cancer stem cells. Cancer Res 2009 Apr 1; 69(7):2887-95. Epub 2009 Mar 10. PMID:19276366. PMCID:PMC2664865.
17. Karp DD, Paz-Ares LG, Novello S, Haluska P, Garland L, Cardenal F, Blakely LJ, Eisenberg PD, Langer CJ, Blumenschein G, Johnson FM, Green S, Gualberto A. Phase II study of the anti-insulin-like growth factor type 1 receptor antibody cp-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer. J Clin Oncol 2009 May 20; 27(15):2516-22. Epub 2009 Apr 20. PMID:19380445. DOI:10.1200/JCO.2008.19.9331.
18. Miller AJ, Markovic SN, Haluska P Jr. The pathway ahead in melanoma trials. Oncology (Williston Park) 2009 May; 23(6):496, 498, 500. PMID:19544690.
19. *McKian KP, Haluska P. Cixutumumab. Expert Opin Investig Drugs 2009 Jul; 18(7):1025-33. PMID:19548856. PMCID:PMC2939377. DOI:10.1517/13543780903055049.
20. Karp DD, Pollak MN, Cohen RB, Eisenberg PD, Haluska P, Yin D, Lipton A, Demers L, Leitzel K, Hixon ML, Terstappen LW, Garland L, Paz-Ares LG, Cardenal F, Langer CJ, Gualberto A. Safety, pharmacokinetics, and pharmacodynamics of the insulin-like growth factor type 1 receptor inhibitor figitumumab (CP-751,871) in combination with paclitaxel and carboplatin. J Thorac Oncol 2009 Nov; 4(11):1397-403. PMID: 19745765. PMCID:PMC2941876. DOI:10.1097/JTO.0b013e3181ba2f1d.
21. *Wahner Hendrickson AE, Haluska P, Schneider PA, Loegering DA, Peterson KL, Attar R, Smith BD, Erlichman C, Gottardis M, Karp JE, Carboni JM, Kaufmann SH. Expression of insulin receptor isoform A and insulin-like growth factor-1 receptor in human acute myelogenous leukemia: Effect of the dual-receptor inhibitor BMS-536924 in vitro. Cancer Res 2009 Oct 1; 69(19): 7635-43. Epub 2009 Sep 29. PMID:19789352. PMCID:PMC2762725.
22. *Hendrickson AW, Haluska P. Resistance pathways relevant to insulin-like growth factor-1 receptor-targeted therapy. Curr Opin Investig Drugs 2009 Oct; 10(10):1032-40 PMID:19777391. PMCID in process.
23. Holtan SG, Creedon DJ, Haluska P, Markovic SN. Cancer and pregnancy: parallels in growth, invasion, immune modulation, and implications for cancer therapeutics. Mayo Clin Proc 2009 Nov; 84(11):985-1000. PMID:19880689. PMCID:PMC2770910.
24. *Olmos D, Postel-Vinay S, Molife LR, Okuno SH, Schuetze SM, Paccagnella ML, Batzel GN, Yin D, Pritchard-Jones K, Judson I, Worden FP, Gualberto A, Scurr MR, de Bono JS, Haluska P. Safety, pharmacokinetics, and preliminary activity of the anti-IGFR-IR antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing’s sarcoma: a phase 1 expansion cohort study. Lancet Oncol 2010 Feb; 11(2):129-35. Epub 2009 Dec 23. PMID: 20036194. PMCID:PMC2941877. DOI:10.1016/S1470-2045(09)70354-7.
25. *Hubbard J, Erlichman C, Toft DO, Qin R, Stensgard BA, Felten S, Ten Eyck C, Batzel G, Ivy SP, Haluska P. Phase I study of 17-allylamino-17 demethoxygeldanamycin, gemcitabine and/or cisplatin in patients with refractory solid tumors. Invest New Drugs 2011 June; 29(3); 473-80. Epub 2010 Jan 15. PMID:20082116. PMCID:PMC290718. DOI:10.1007/s10637-009-9381-y.
26. Galanis E, Hartmann LC, Cliby WA, Long HJ, Peethambaram PP, Barette BA, Kaur JS, Haluska PJ Jr, Aderca I, Zollman PJ, Sloan JA, Keeney G, Atherton PJ, Podratz KC, Dowdy SC, Stanhope CR, Wilson TO, Federspiel MJ, Peng KW, Russell SJ. Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. Cancer Res 2010 Feb 1; 70(3):875-82. Epub 2010 Jan 26. PMID:20103634. PMCID:PMC2890216. DOI:10.1158/0008-5472.CAN- 09-2762.
27. Haluska P, Worden F, Olmos D, Yin D, Schteingart D, Batzel GN, Paccagnella ML, de Bono JS, Gualberto A, Hammer GD. Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma. Cancer Chemother Pharmacol 2010 Mar; 65(4):765-73. Epub 2009 Aug 02. PMID:19649631. PMCID:PMC2875253. DOI:10.1007/s00280-009-1083-9.
28. Huntoon CJ ,Nye MD, Geng L, Peterson KL, Flatten KS, Haluska P, Kaufmann SH, Karnitz LM. Heat shock protein 90 inhibition depletes LATS1 and LATS2, two regulators of the mammalian hippo tumor suppressor pathway. Cancer Res 2010 Nov 1;70(21):8642-50. Epub 2010 Sep 14. PMID:20841485. PMCID:PMC2970685. DOI:10.1158/0008-5472.
29. Gilbert JA, Adhikari LJ, Lloyd RV, Rubin J, Haluska P, Carboni JM, Gottardis MM, Ames MM. Molecular markers for novel therapies in neuroendocrine (carcinoid) tumors. Endocr Relat Cancer 2010 Sep; 17(3):623-36. Epub 2010 Jun 25. PMID:20385747. PMCID in process. DOI:10.1677/ERC-09-0318.
30. Haluska P. Insulin-like growth factor pathway. J Thorac Oncol 2010 Dec;5(12 Suppl 6):S478-9. PMID:21102247. PMCID in process. DOI:10.1097/01.JTO.0000391374.71505.a2.
31. *Sirop SJ, Haluska P. Insulin-like growth factor pathway-targeted therapy in breast cancer. Current Breast Cancer Reports 2011; 3(1):6-14.
32. *Hou X, Huang F, Carboni JM, Flatten K, Asmann YW, Ten Eyck C, Nakanishi T, Tibodeau JD, Ross DD, Gottardis MM, Erlichman C, Kaufmann SH, Haluska P. Drug Efflux by Breast Cancer Resistance Protein Is a Mechanism of Resistance to the Benzimidazole Insulin-Like Growth Factor Receptor/Insulin Receptor Inhibitor, BMS-536924. Mol Cancer Ther. 2011 Jan;10(1):117-25. PMID:21220496. PMCID:PMC3057506. DOI:10.1158/1535-7163.
33. *Weroha SJ, Oberg AL, Ziegler KL, Dakhilm SR, Rowland KM, Hartmann LC, Moore DF Jr, Keeney GL, Peethambaram PP, Haluska P. Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma. Gynecol Oncol 2011 Jul;122(1):116-20. Epub 2011 Apr 22. PMID: 21514634. PMCID:PMC3104066. DOI:10.1016/j.ygyno.2011.03.030.
34. *Bryce AH, Rao R, Sarkaria J, Reid JM, Qi Y, Qin R, James CD, Jenkins RB, Boni J, Erlichman C, Haluska P. Phase I study of temsirolimus in combination with EKB-569 in patients with advanced solid tumors. Invest New Drugs 2012 Oct;30(5):1934-41. Epub 2011 Sep 1. PMID:21881915. DOI: 10.1007/s10637-011-9742-1.
35. *Hou X, Huang F, Macedo LF, Harrington SC, Reeves KA, Finckenstein F, Brodie A, Gottardis MM, Carboni JM, Haluska P. Dual IGF-1R/InsR inhibitor BMS-754807 synergizes with hormonal agents in treatment of estrogen-dependent breast cancer. Cancer Res. 2011 Dec 15; 71(24):7597-607. Epub 2011 Oct 31. PMID:22042792. PMCID in process. DOI:10.1158/0008-5472.
36. O'Bryant CL, Haluska P, Rosen L, Ramanathan RK, Venugopal B, Leong S, Boinpally R, Franke A, Witt K, Evans J, Belani C, Gail Eckhardt S, Ramalingam S. An open-label study to describe pharmacokinetic parameters of erlotinib in patients with advanced solid tumors with adequate and moderately impaired hepatic function. Cancer Chemother Pharmacol 2012 Mar; 69(3):605-12. Epub 2011 Sep 22. PMID:21938545. PMCID in process. DOI:10.1007/s00280- 011-1733-6.
37. *Wahner Hendrickson AE, Oberg AL, Glaser G, Camoriano JK, Peethambaram PP, Colon- Otero G, Erlichman C, Ivy P, Kaufmann SH, Karnitz LM, Haluska P. A Phase II Study of Gemcitabine in Combination with Tanespimycin in Advanced Epithelial Ovarian and Primary Peritoneal Carcinoma. Gynecol Oncol 2012 Feb; 124(2):210-5. Epub 2011 Nov 1. PMID:22047770. PMCID:PMC3265019. DOI:10.1016/j.ygyno.2011.
38. *Becker MA, Hou X, Harrington SC, Weroha SJ, Gonzalez SE, Jacob KA, Carboni JM, Gottardis MM, Haluska P. IGFBP ratio confers resistance to IGF targeting and correlates with increased invasion and poor outcome in breast tumors. Clin Cancer Res 2012 Mar 15;18(6):1808-17. Epub 2012 Jan 27. PMID:22287600. PMCID:PMC3306532. DOI:10.1158/1078-0432.CCR-11-1806.
39. *Weroha SJ, Haluska P. The insulin-like growth factor system in cancer. Endocrinol Metab Clin North Am 2012 Jun; 41(2):335-50. PMID:22682634. PMCID:PMC3614012. DOI:10.1016/j.ecl.2012.04.014.
40. Holtan SG, Mansfield AS, Creedon DJ, Nevala WK, Haluska P, Leontovich AA, Markovic SN. An organ system based approach to prognosis in advanced melanoma. Front Biosci (Elite Ed) 2012 Jun 1; 4:2823-33. PMID:22652681. PMCID in process.
41. *Harrington SC, Weroha SJ, Reynolds C, Suman VJ, Lingle WL, Haluska P. Quantifying Insulin Receptor Isoform Expression in FFPE Breast Tumors. Growth Horm IGF Res 2012 Jun-Aug; 22(3-4):108-15. PMID:22551578. PMCID:PMC3392524. DOI:10.1016/j.ghir.2012.04.001.
42. *Hendrickson AE, Oberg AL, Glaser G, Camoriano JK, Peethambaram PP, Colon-Otero G. Erlichman C, Ivy SP, Kaufmann SH, Karnitz LM, Haluska P. A phase II study of gemcitabine in combination with tanespimycin in advanced epithelial ovarian and primary peritoneal carcinoma. Gynecol Oncol 2012 Feb; 124(2):210-5. PMID:22047770. PMCID:PMC3265019. DOI:10.1016/j.ygyno.2011.10.002.
43. *Becker MA, Hou X, Harrington SC, Weroha SJ, Gonzalez SE, Jacob KA, Carboni JM, Gottardis MM, Haluska P. IGFBP ratio confers resistance to IGF targeting and correlates with increased invasion and poor outcome in breast tumors. Clin Cancer Res 2012 Mar 15; 18(6):1808-17. Epub 2012 Jan 27. PMID:22287600. PMCID:PMC3306532. DOI:10.1158/1078-0432.CCR-11-1806.
44. *Weroha SJ, Haluska P. The insulin-like growth factor system in cancer. Endocrinol Metab Clin North Am 2012 Jun; 41(2):335-50, vi. PMID:22682634. PMCID:PMC3614012. DOI:10.1016/j.ecl.2012.04.014.
45. *Harrington SC, Weroha SJ, Reynolds C, Suman VJ, Lingle WL, Haluska P. Quantifying insulin receptor isoform expression in FFPE breast tumors. Growth Horm IGF Res. 2012 Jun-Aug; 22(3-4):108-15. Epub 2012 Apr 30. PMID:22551578. PMCID:PMC3392524. DOI:10.1016/j.ghir.2012.04.001.
46. Modugno F, Laskey R, Smith AL, Andersen CL, Haluska P, Oesterreich S. Hormone response in ovarian cancer: time to reconsider as a clinical target? Endocr Relat Cancer 2012 Dec; 19(6):R255-79. Epub 2012 Nov 09. PMID:23045324. PMCID:PMC3696394. DOI:10.1530/ERC-12-0175.
47. Liang JJ, Kizilbash SH, Haluska P. Intrathecal metastases causing conus medullaris syndrome. QJM 2013 Jan 21. [Epub ahead of print] PMID:23340390. DOI:10.1093/qjmed/hct008.
48. Demichele A, Berry DA, Zujewski J, Hunsberger S, Rubinstein L, Tomaszewski JE, Kelloff G, Perlmutter J, Buxton M, Lyandres J, Albain KS, Benz C, Jo Chien A, Haluska P, Leyland-Jones B, Liu MC, Munster P, Olopade O, Park JW, Parker BA, Pusztai L, Tripathy D, Rugo H, Yee D, Esserman L. Developing Safety Criteria for Introducing New Agents into Neoadjuvant Trials. Clin Cancer Res 2013 Jun 1; 19(11):2817-23. Epub 2013 Mar 7. PMID:23470967. DOI:10.1158/1078-0432.CCR-12-2620.
49. Yee D, Haddad T, Albain K, Barker A, Benz C, Boughey J, Buxton M, Chien AJ, DeMichele A, Dilts D, Elias A, Haluska P, Hogarth M, Hu A, Hytlon N, Kaplan HG, Kelloff GG, Khan Q, Lang J, Leyland-Jones B, Liu M, Nanda R, Northfelt D, Olopade OI, Park J, Parker B, Parkinson D, Pearson-White S, Perlmutter J, Pusztai L, Symmans F, Rugo H, Tripathy D, Wallace A, Wholley D, Van't Veer L, Berry DA, Esserman L. Adaptive trials in the neoadjuvant setting: a model to safely tailor care while accelerating drug development. J Clin Oncol 2012 Dec 20; 30(36):4584-6; author reply 4588-9. Epub 2012 Nov 19. PMID:23169510. DOI:10.1200/JCO.2012.44.1022.
50. Ma CX, Suman VJ, Goetz M, Haluska P, Moynihan T, Nanda R, Olopade O, Pluard T, Guo Z, Chen HX, Erlichman C, Ellis MJ, Fleming GF. A phase I trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancer. Breast Cancer Res Treat 2013 May; 139(1):145-53. Epub 2013 Apr 19. PubMed PMID: 23605083. DOI:10.1007/s10549-013-2528-8.
51. Chae YK, Hu MI, Katz RL, Chavez-Macgregor M, Haluska P, Meric-Bernstam F, Gonzalez- Angulo AM, Melhem-Bertrandt A. Two birds with one stone: octreotide treatment for acromegaly and breast cancer. J Clin Oncol 2013 Aug 10; 31(23):e398-400. Epub 2013 Jun 24. PMID:23796991. DOI:10.1200/JCO.2012.46.6383.
52. Lengyel E, Burdette JE, Kenny HA, Matei D, Pilrose J, Haluska P, Nephew KP, Hales DB, Stack MS. Epithelial ovarian cancer experimental models. Oncogene 2013 Aug 12. [Epub ahead of print] PMID:23934194. DOI:10.1038/onc.2013.321.
53. *Becker MA, Farzan T, Harrington SC, Krempski JW, Weroha SJ, Hou X, Kalli KR, Wong TW, Haluska P. Dual HER/VEGF receptor targeting inhibits in vivo ovarian cancer tumor growth. Mol Cancer Ther. 2013 Dec;12(12):2909-16. Epub 2013 Oct 15. PMID:24130056 PMCID:PMC3880137
54. Scott CL, Mackay HJ, Haluska P Jr. Patient-derived xenograft models in gynecologic malignancies. Am Soc Clin Oncol Educ Book. 2014; 34:e258-66. PMID:24857111
55. *Weroha SJ, Becker MA, Enderica-Gonzalez S, Harrington SC, Oberg AL, Maurer MJ, Perkins SE, AlHilli M, Butler KA, McKinstry S, Fink S, Jenkins RB, Hou X, Kalli KR, Goodman KM, Sarkaria JN, Karlan BY, Kumar A, Kaufmann SH, Hartmann LC, Haluska P. Tumorgrafts as in vivo surrogates for women with ovarian cancer. Clin Cancer Res. 2014 Mar 1;20(5):1288-97. PMID:24398046 PMCID:PMC3947430
56. King H, Aleksic T, Haluska P, Macaulay VM. Can we unlock the potential of IGF-1R inhibition in cancer therapy? Cancer Treat Rev. 2014 Aug 4. PMID:25123819
57. Haluska P, Menefee ME, Plimack ER, Rosenberg JE, Northfelt DW, LaVallee T, Shi L, Yu XQ, Burke PA, Huang J, Viner J, McDevitt J, LoRusso PM. Phase I Dose Escalation Study of MEDI-573, a Bispecific, Anti-ligand Monoclonal Antibody against IGF-I and IGF-II, in Patients with Advanced Solid Tumors. Clin Cancer Res. 2014 Jul 14. [Epub ahead of print] PMID:25024259
58. Penson RT, Moore KM, Fleming GF, Braly P, Schimp V, Nguyen H, Matulonis UA, Banerjee S, Haluska P, Gore M, Bodurka DC, Hozak RR, Joshi A, Xu Y, Schwartz JD, McGuire WP. A phase II study of ramucirumab (IMC-1121B) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma. Gynecol Oncol. 2014 Jul 10. pii: S0090-8258(14)01070-1. [Epub ahead of print] PMID:25016924
59. Scott CL, Mackay HJ, Haluska P Jr. Patient-derived xenograft models in gynecologic malignancies. Am Soc Clin Oncol Educ Book. 2014:e258-66. PMID: 24857111
60. Leal AD, Qin R, Atherton PJ, Haluska P, Behrens RJ, Tiber CH, Watanaboonyakhet P, Weiss M, Adams PT, Dockter TJ, Loprinzi CL; Alliance for Clinical Trials in Oncology. North Central Cancer Treatment Group/Alliance trial N08CA-the use of glutathione for prevention of paclitaxel/carboplatin-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled study. Cancer. 2014 Jun 15;120(12):1890-7. doi: 10.1002/cncr.28654. Epub 2014 Mar 11. PMID:24619793[PubMed - in process] PMCID:PMC4047184
61. Mahadevan D, Sutton GR, Arteta-Bulos R, Bowden CJ, Miller PJ, Swart RE, Walker MS, Haluska P, Munster PN, Marshall J, Hamid O, Kurzrock R. Phase 1b study of safety, tolerability and efficacy of R1507, a monoclonal antibody to IGF-1R in combination with multiple standard oncology regimens in patients with advanced solid malignancies. Cancer Chemother Pharmacol. 2014 Mar;73(3):467-73. doi: 10.1007/s00280-013-2372-x. Epub 2014 Jan 4.
62. Reid JM, Goetz MP, Buhrow SA, Walden C, Safgren SL, Kuffel MJ, Reinicke KE, Suman V, Haluska P, Hou X, Ames MM. Pharmacokinetics of endoxifen and tamoxifen in female mice: implications for comparative in vivo activity studies. Cancer Chemother Pharmacol. 2014 Dec;74(6):1271-8. doi: 10.1007/s00280-014-2605-7. Epub 2014 Oct 16. PubMed PMID: 25318936.
63. Brana I, Berger R, Golan T, Haluska P, Edenfield J, Fiorica J, Stephenson J, Martin LP, Westin S, Hanjani P, Jones MB, Almhanna K, Wenham RM, Sullivan DM,Dalton WS, Gunchenko A, Cheng JD, Siu LL, Gray JE. A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours. Br J Cancer. 2014 Nov 11;111(10):1932-44. doi: 10.1038/bjc.2014.497. Epub 2014 Oct 7. PubMed PMID: 25290091; PubMed Central PMCID: PMC4229637.
64. Galanis E, Atherton PJ, Maurer MJ, Knutson KL, Dowdy SC, Cliby WA, Haluska P Jr, Long HJ, Oberg A, Aderca I, Block MS, Bakkum-Gamez J, Federspiel MJ, Russell SJ, Kalli KR, Keeney G, Peng KW, Hartmann LC. Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer. Cancer Res. 2015 Jan 1;75(1):22-30. doi: 10.1158/0008- 5472.CAN-14-2533. Epub 2014 Nov 14. PubMed PMID: 25398436.
65. *Becker MA, Haluska P, Bale LK, Oxvig C, Conover CA. A Novel Neutralizing Antibody Targeting Pregnancy-Associated Plasma Protein-A Inhibits Ovarian Cancer Growth and Ascites Accumulation in Patient Mouse Tumorgrafts. Mol Cancer Ther. 2015 Feb 18. pii: molcanther.0880.2014. [Epub ahead of print] PubMed PMID: 25695953.
66. DeMichele A, Yee D, Berry DA, Albain KS, Benz CC, Boughey J, Buxton M, Chia SK, Chien AJ, Chui SY, Clark A, Edmiston K, Elias AD, Forero-Torres A, Haddad TC, Haley B, Haluska P, Hylton NM, Isaacs C, Kaplan H, Korde L, Leyland-Jones B, Liu MC, Melisko M, Minton SE, Moulder SL, Nanda R, Olopade OI, Paoloni M, Park JW, Parker BA, Perlmutter J, Petricoin EF, Rugo H, Symmans F, Tripathy D, Van't Veer LJ, Viscusi RK, Wallace A, Wolf D, Yau C, Esserman LJ. The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer. Clin Cancer Res. 2015 Jul1;21(13):2911-5. doi: 10.1158/1078-0432.CCR-14-1760. Epub 2015 Feb 24. PubMed PMID: 25712686; PubMed Central PMCID: PMC4490043.
67. Forero-Torres A, Varley KE, Abramson VG, Li Y, Vaklavas C, Lin NU, Liu MC, Rugo HS, Nanda R, Storniolo AM, Traina TA, Patil S, Van Poznak CH, Nangia JR, Irvin WJ Jr, Krontiras H, De Los Santos JF, Haluska P, Grizzle W, Myers RM, Wolff AC; Translational Breast Cancer Research Consortium (TBCRC). TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-Negative Breast Cancer. Clin Cancer Res. 2015 Jun 15;21(12):2722-9. doi:10.1158/1078-0432.CCR-14-2780. Epub 2015 Mar 16. PubMed PMID: 25779953.
68. *Lodhia KA, Hadley AM, Haluska P, Scott CL. Prioritizing therapeutic targets using patient- derived xenograft models. Biochim Biophys Acta. 2015 Apr;1855(2):223-234. doi: 10.1016/j.bbcan.2015.03.002. Epub 2015 Mar 14. Review. PubMed PMID: 25783201; PubMed Central PMCID: PMC4433556. 69. *Glaser G, Weroha SJ, Becker MA, Hou X, Enderica-Gonzalez S, Harrington SC, Haluska P. Conventional chemotherapy and oncogenic pathway targeting in ovarian carcinosarcoma using a patient-derived tumorgraft. PLoS One. 2015 May 11;10(5):e0126867. doi: 10.1371/journal.pone.0126867. eCollection 2015. PubMed PMID: 25962155; PubMed Central PMCID: PMC4427104.
70. *Lodhia KA, Tienchaiananda P, Haluska P. Understanding the Key to Targeting the IGF Axis in Cancer: A Biomarker Assessment. Front Oncol. 2015 Jul 8;5:142. doi:10.3389/ fonc.2015.00142. eCollection 2015. Review. PubMed PMID: 26217584; PubMed Central PMCID: PMC4495315.
Non-peer-reviewed Articles
71. Li X-G, Haluska P, Hsiang YH, Bharti A, Kufe DW, Rubin EH. Identification of topoisomerase I mutations affecting both DNA cleavage and interaction with camptothecin. Ann N Y Acad Sci 1996 Dec 13; 803:111-27. PMID:8993505
72. Haluska P, Rubin EH. A role for the amino terminus of human topoisomerase I. Adv Enzyme Regul 1998; 38:253-62. PMID:9762357.
73. Haluska P, Rubin E, Verschraegen CF. Topoisomerase-I inhibitors in gynecologic tumors. Hematol Oncol Clin North Am 1999 Feb; 13(1):43-61, vii-viii. PMID:10080069.
Editorials
74. Miller AJ, Markovic SN, Haluska P Jr. The pathway ahead in melanoma trials. Oncology (Williston Park) 2009 May; 23(6): 496, 498, 500. PMID:19544690.
75. Wahner-Hendrickson AE, Haluska P, Erlichman C, Gottardis M, Carboni JE, Karp JE, Kaufmann SH. Insulin Receptor A and IGF-IR in AML – Response. Cancer Res 2010 Sep 1; 70(17):7011. Epub 2010 Aug 10. PMID:20699368.
Abstracts and Letters
76. Toppmeyer D, Haluska P, Li X-G, Goodin S, Orlick M, Aisner J, Rubin EH. Sequential camptothecin and etoposide in the treatment of refractory malignancies. Annual Retreat on Cancer Research. Princeton, New Jersey. 05/31/1996. (Abstract)
77. Saleem A, Toppmeyer D, Gupta E, Zamek R, Much J, Ibrahim N, Bindi M, Haluska P, Li X-G, Goodin S, Aisner J, Natelson E, Giovanella B, Rubin EH. Analysis of topoisomerase I and II protein levels in a clinical trial of sequential camptothecin and etoposide. Poster Presentation. The Seventh Conference on DNA Topoisomerases in Therapy- NYU Medical Center and The Kaplan Cancer Center. 10/21/1996 - 10/24/1996. (Abstract)
78. Toppmeyer D, Gupta E, Saleem A, Zameck R, Much J, Ibrahim N, Bindi H, Haluska P, Li XG, Goodin S, Aisner J, Natelson N, Giovanella B, Rubin EH. A Phase I Pharmacokinetic and Pharmacodynamic Study of Camptothecin and Etoposide in Patients with Advanced Malignancies. Annual Retreat on Cancer Research. Princeton, New Jersey. 05/30/1997. (Abstract)
79. Rasheed Z, Haluska P, Saleem A, Rubin EH. Identification of a novel protein that binds to human topoisomerase I. Poster Presentation. 1999 AACR Annual Meeting. 04/10/1999- 04/14/1999. (Abstract)
80. Allen RD, Haluska P, Bergstrom L. Non-surgical Free Intraperitoneal Air. Minnesota American College of Physician Annual Meeting. Bloomington, Minnesota. 10/25/2002. (Abstract)
81. Allen RD, Haluska P, Bergstrom L. Postinfectious Glomerulonephritis & Furosemide-Induced Interstitial Nephritis. Minnesota American College of Physician Annual Meeting. Bloomington, Minnesota. 10/25/2002. (Abstract)
82. Saulnier MG, Velaparthil U, Frennesson1 DB, Liu P, Zimmermann K, Sang X, Eummer J, Bedingfield K, Lee FT, Carboni JM, Vyas DM, Haluska P, Loegering DA, Kaufmann SH, Erlichman C, Attar R, Gottardis G, Wittman M. SAR of a series of 3-[6-(4-substituted-piperazin- 1-yl)-4-methyl-1H-benzimidazol-2-yl]-1H-pyridin-2-one inhibitors of the IGF-1 receptor kinase with in vivo antitumor activity. Proceedings of the 229th National Meeting of the American Chemical Society. San Diego, California. 03/13/2005 - 03/17/2005. (Abstract)
83. Wahner Hendrickson AE, Karp JE, Carboni J, Attar RM, Smith BD, Whittman M, Gottardis M, Haluska PJ, Kaufmann SH. . Apoptotic and anti-proliferative effects of the dual insulin-like growth factor-1(IGF-1R)/insulin receptor inhibitor, BMS 536924, in acute myelogenous leukemia. Poster Presentation. 2007 AACR Annual Meeting. Los Angeles, California. 04/14/2007 - 04/18/2007. (Abstract)
84. de Bono JS, Adjei A, Attard G, Pollak M, Fong P, Haluska P, Roberts L, Chainese D, Terstappen L, Gualberto A. Circulating tumor cells expressing the insulin growth factor-1 receptor (IGF-1R); Method of detection, incidence and potential applications. Oral Presentation. 2007 ASCO Annual Meeting. Chicago, Illinois. 06/01/2007 - 06/05/2007. (Abstract)
85. Santisebant M, Reiman JM, Behrens MD, Haluska P, Mukherjee P, Bhattacharya R, Ferrone S, Kalli KR, Knutson KL. Immunoedited breast tumor cells demonstrate characteristics of both mesenchymal and cancer stem cells. J Immunother. 2007 Nov-Dec; 30(8):889-90. (Abstract)
86. Olmos D, Molife R, Okuno S, Worden F, Hammer G, Yap T, Shaw H, Schuetze S, Roberts L, Gualberto A, De-Bono J, Haluska P. Safety, tolerability and preliminary efficacy of the anti-IGF- IR monoclonal antibody CIP-751,871 in patients with sarcomas and achrenocortical tumors. Mol Cancer Ther 2007 Dec; 6(12):3355S. (Abstract)
87. Haluska P, Stensgard BA, Qin R, Felton SJ, Batzel GN, Ivy SP, Toft DO, Erlichman C. Phase I study of 17-allylamino-17 demethoxygeldanamycin (17-AAG), gemcitabine (Gem) and/or cisplatin (CDDP) in solid tumor patients. Ann Oncol. 2008; 19(Suppl 3):34. (Abstract)
88. Gualberto A, Melvin CL, Dean A, Ang AL, Reynolds JM, Lee AV, Terstappen LW, Haluska P, Lipton A, Karp DD. Characterization of NSCLC patients responding to anti-IGF-IR therapy. Oral Presentation. 2008 ASCO Annual Meeting. Chicago, Illinois. 05/30/2008 - 06/03/2008. (Abstract)
89. Karp DD, Paz-Ares LD, Novello S, Haluska P, Garland L, Cardenal F, Blakely LJ, Eisenberg PD, Gualberto A, Langer CJ. High activity of the anti-IGF-IR antibody CP-751,871 in combination with paclitaxel and carboplatin in squamous NSCLC. Oral Presentation. 2008 ASCO Annual Meeting. Chicago, Illinois. 05/30/2008 - 06/03/2008. (Abstract)
90. Olmos D, Okuno S, Schuetz SM, Paccagnella ML, Yin D, Gualberto A, Worden FP, Haluska P, De Bono JS, Scurr M. Safety, pharmacokinetics and preliminary activity of the anti-IGF-IR antibody CP-751,871 in patients with sarcoma. 2008 ASCO Annual Meeting (oral presentation). Chicago, IL. 2008 May 30-Jun 3. (Abstract)
91. Yin D, Paccagnella ML, Lacy MQ, De Bono JS, Haluska P, Gualberto A, Sharma A. Population pharmacokinetics of CP-751,871, a monoclonal antibody against IGF-1 receptor, in patients with multiple myeloma or solid tumors. Poster Discussion Presentation. 2008 ASCO Annual Meeting. Chicago, Illinois. 05/30/2008 - 06/03/2008. (Abstract)
92. Gualberto A, Melvin CL, Dean A, Ang AL, Reynolds J, Lee AV, Terstappen LW, Haluska P, Lipton A, Karp DD. Igf-Ir markers in NSCLC patients on anti-Igf-Ir therapy. Ann Oncol 2008 Sep; 19(Suppl 8):62. (Abstract)
93. Karp DD, Paz-Ares L, Novello S, Haluska P, Garland L, Cardenal F, Blakely LJ, Eisenberg PD, Gualberto A, Langer C. Addition of Cp-751,871, an anti-Igf-Ir antibody, to paclitaxel and carboplatin results in high activity in non-small cell lung cancer (Nsclc), particularly in the squamous subtype. Ann Oncol 2008 Sep; 19(Suppl 8):90. (Abstract)
94. Haluska P, Carboni JM, Asmann YW, Ten Eyck C, Allar RM, Tibodeau JD, Hou X, Nakanishi T, Ross DD, Kaufmann SH, Gottardis MM, Erlichman C. Drug efflux by breast cancer resistance protein (BCRP) is a mechanism of resistance to the insulin-like growth factor receptor/insulin receptor inhibitor, BMS-536924. Cancer Res 2008 Jan; 69(2 Suppl S):200S. (Abstract)
95. *Harrington S, Hou X, Macedo L, Weroha J, Brodie A, Haluska P. Insulin Receptor A isoform and erbB receptor up-regulated in response to IGF-1R targeted therapy. Poster Presentation. Gordon Research Conference. Ventura, California. 03/22/2009 - 03/27/2009. (Abstract)
96. *Hou X Carboni J Macedo L Harrington S Finckenstein F Brodie A Gottardis M, Haluska P. Combined estrogen signaling inhibition and IGF-1R/InsR inhibition with BMS-754807 in estrogen dependent breast cancer model has synergistic antitumor activity in vitro and in vivo. Poster Presentation. 100th Annual AACR Meeting 2009. Denver, Colorado. 04/18/2009 - 04/22/2009. (Abstract)
97. *Hou X, Harrington S, Macedo L, Weroha J, Brodie A, Haluska P. Hormonal therapies differentially enhance insulin receptor isoform A and erbB receptor up-regulation in response to IGF-1R inhibitor MK-0646 in vivo. Poster Presentation. 100th Annual AACR Meeting 2009. Denver, Colorado. 04/18/2009 - 04/22/2009. (Abstract)
98. Haluska P, Oberg AL, Dakhil SR, Ziegler KLA, Rowland KM, Hartmann LC, Moore DF, Keeney GL, Peethambaram PP. Phase II trial of lapatinib in combination with weekly topotecan in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma. Ann Oncol 2009 May; 20:43. (Abstract)
99. Haluska P, Worden F, Olmos D, Yin D, Schteingart D, Batzel GNW, Paccagnella ML, De Bono JS, Gualberto A, Hammer GD. Safety, tolerability, and pharmacokinetics of the anti-IgF-1R monoclonal antibody CP-751,871 in patients with refractory adrenocortical carcinoma. Ann Oncol 2009 May; 20:42. (Abstract)
100. Karp DD, Novello S, Cardenal F, Haluska P, Blakely LJ, Garland L, Paz-Ares LG, Dolled-Filhart MP, Johnson ED, Gualberto A. Continued high activity of figitumumab (CP-751,871) combination therapy in squamous lung cancer. J Clin Oncol 2009 May 20; 27(Suppl S):8072. (Abstract)
101. Haluska P, Hou X, Huang F, et al. Complete IGF Signaling Blockade by the Dual-Kinase Inhibitor, BMS-754807, Is Sufficient To Overcome Tamoxifen and Letrozole Resistance In Vitro and In Vivo. Cancer Res 2009;69(24 Suppl):Abstract nr 402 (Abstract)
102. Haluska P, Harrington SC, Farzan T, Winterhoff BJ, Goodman KM, Kalli KK, Gottfried KE. Low expression of insulin-like growth factor binding proteins predicts poor outcomes in ovarian cancer patients. AACR/JCA Joint Conference: Genomics, Epigenomics, and the Development of Novel Therapeutics. Waikoloa, Hawaii. 2010 Feb 6. (Abstract)
103. Haluska P, Reinholz MM, Dueck AC, Linden HM, Lingle WL, Bernath AM, Arbushites MC, Youssoufian H, Chen HX, Perez EA. N0733: Phase II Trial of Capecitabine and Lapatinib +/- Cixutumumab in HER2 Positive Breast Cancer. [Abstract #TPS129]. J Clin Oncol 2010 May; 28(15s):14s. (Abstract)
104. Erlichman C, Menefee ME, Northfelt DW, Qin R, Reid JM, Oursler M, Marks R, Molina JR, Haluska P, Koch K. Phase I trial of dasatinib (D) and lapatinib (L). J Clin Oncol 06/07/2010; 28(15s (abstr 2610)). (Abstract)
105. Menefee ME, LoRusso P, Viner J, McDevitt J, Huang W, Lam B, Jin F, Chang Y, Haluska P. MEDI-573, a dual IGF-1/-2 neutralizing antibody, blocks IGF-1R and IR-A signaling and maintains glucose homeostasis in a Phase 1 study for advanced solid tumors. 22nd EORTC- NCI-AACR symposium on Molecular Targets and Cancer Therapeutics," Berlin, Germany Nov 16-19 2010. (Oral - Plenary Session)
106. *Becker M, Hou X, Harrington SC, Carboni JM, Gottardis MM, Haluska P. IGFBP5 confers resistance to IGF targeting and correlates with increased invasion and poor overall survival in breast tumors. Gordon Conference: Insulin-Like Growth Factors in Physiology & Disease, Ventura, CA Feb 27-Mar 4, 2011. (Oral - Selected Presentation)
107. Haluska P, Dhar A, Hou X, Huang F, Nuyten DSA, Park JS, Brodie AH, Ingle JN, Carboni JM, Gottardis MM, Wolff AC, Finckenstein FG. Phase II trial of the dual IGF-1R/IR inhibitor BMS- 754807 with or without letrozole in aromatase inhibitor-resistant breast cancer. Trials in Progress, 2011 ASCO Annual Meeting, Chicago, Illinois, June 3-7, 2011. (Poster Presentation)
108. Haluska P, Hou X, Dhar A, Yee D, Suman VJ, Harrington SC, Finckenstein F, Ingle JN. Regulation of Hormone-resistant Breast Cancer by IGF and Insulin System Signaling. Poster Discussion, NCI Translational Science Meeting 2011, Washington, DC, July 28-29.
109. P. Haluska, J. Huang, B. Lam, X. Chen, W. Huang, P. LoRusso, M.E. Menefee, T. LaVallee, Y. Yao, J. Viner. MEDI-573--a novel approach to IGF-1R and IR-A signaling inhibition by blocking IGF ligands: Phase 1 PK/PD, safety data, and disease linkage studies in breast cancer. ASCO Breast Cancer Symposium, San Francisco, CA, Sept 8-10, 2011. (Poster and Oral Presentation)
110. Farzan T, Harrington S, Krempski J, Weroha S, Hou X, Kalli K, Haluska P. Combined erbB/VEGFR blockade has improved anticancer activity over single-pathway inhibition in ovarian cancer in vivo. Gynecol Oncol. 2011 Mar; 121(Suppl 1):S45.
111. Winterhoff B, Haluska P, Kalli K, Cliby W, Gostout B, Oberg A, Maurer M, Hartmann L, Slamon D, Konecny G. Insulin-like growth factor receptor 1 pathway signature correlates with adverse clinical outcome in ovarian cancer. Gynecol Oncol. 2011 Mar; 121(Suppl 1):S71-2.
112. Haluska P, Dudek AZ, Bono P, Sleight B, Joensuu H, Juergens H, Pollak M. Phase I trial of figitumumab and pegvisomant in patients with advanced solid tumors. Ann Oncol. 2011 May; 22(Suppl 3):39.
113. Haluska P, Oberg AL, Glaser G, Gonzalez SE, Becker MA, Jacob KA, Pennil CC, Fink SR, Kalli KR, Swisher EM, Jenkins RB, Sarkaria JN, Karlan BY, Weroha SJ. Ovarian avatar project: a model system for individualizing ovarian cancer therapy. Ann Oncol. 2012 Mar; 23:42.
114. Butler K, Weroha S, Beckre M, Enderica-Gonzalez S, Harrington S, Hou X, Visscher D, Haluska P. Ovarian cancer tumorgraft: viral latency propagates lymphoma. Genecol Oncol. 2012 Oct; 127(1):S16.
115. Haluska P, Menefee ME, Plimack ER, Rosenberg JE, Northfelt DW, LaVallee T, Huang W, Yu XQ, Viner JL, LoRusso P. A phase 1 study of medi-573, an investigational monoclonal antibody that targets IGF-I and IGF-II: safety, pharmacokinectics, and antitumor activity in adults with advanced solid tumors. Eur J Cancer. 2012 Nov; 48:187-8.
116. Weroha SJ, Haluska P, Becker MA, Harrington SC, Goodman KM, Gonzalez SE, al Hilli M, Butler KA, Kalli KR, Oberg AL. Ovarian avatar models predictive of platinum response in ovarian cancer patients. Ann Oncol. 2013 Mar; 24:16.
117. Galanis E, Atherton P, Dowdy S, Cliby W, Haluska P, Long H, Aderca I, Knutson K, Block M, Federspiel M, Russell S, Peng KW, Hartmann L. Intraperitoneal (ip) administration of an oncolytic measles virus (mv) strain expressing the sodium iodine symporter gene in patients (pts) with advanced ovarian cancer (ovca). Mol Ther. 2013 June; 21LS6-7.
* Indicates that the primary author was a mentee of this author.